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6ABSTRACT
Approximately 70% of all colorectal cancers (CRCs) are sporadic, occurring by chance or due to 
environmental factors, and 25-30% have hereditary background.  Hereditary CRC occurs at younger 
age (~ 45 years), compared to sporadic CRC (~70 years). Egyptian sporadic CRC makes an exception 
to the previous rule, since there 60 % of sporadic CRC patients are diagnosed at less than 50 years of 
age. 
Individuals with inherited deficiency in DNA mismatch repair (MMR) (Lynch syndrome) LS are 
predisposed to different cancers in a non-random fashion.  Endometrial cancer (EC) is the most 
common extracolonic malignancy in LS. LS represents the best characterized form of hereditary non-
polyposis colorectal carcinoma (HNPCC).  Other forms of familial non-polyposis colon cancer exist, 
including  familial  colorectal  cancer  type  X  (FCCX).  This  syndrome  resembles  LS,  but  MMR gene  
defects are excluded and the predisposition genes are unknown so far.   
To address why different organs are differently susceptible to cancer development, we examined 
molecular similarities and differences in selected cancers whose frequency varies in LS individuals. 
Tumors that are common (colorectal, endometrial, gastric) and less common (brain, urological) in LS 
were characterized for MMR protein expression, microsatellite instability (MSI), and by altered DNA 
methylation. We also studied samples of histologically normal endometrium, endometrial hyperplasia, 
and cancer for molecular alterations to identify potential markers that could predict malignant 
transformation in LS and sporadic cases. 
CRC, EC, gastric, and uroepithelial cancers showed MSI by conventional methods, but brain tumors 
did not show MSI. Also methylation and Wnt-signalling pathway activation status distinguished brain 
and kidney tumors from CRC, EC, and gastric cancers, suggesting that brain and kidney tumors 
follow a different pathway for cancer development than the most common LS related cancers. 
Our results suggest that MMR defects are detectable in endometrial tissues from a proportion of LS 
mutation carriers prior to endometrial cancer development. Traditionally (complex) atypical 
hyperplasia has been considered critical for progression to malignancy.  Our results suggest that 
complex hyperplasia without atypia is equally important as a precursor lesion of malignancy. 
Tumor profiles from Egypt were compared with colorectal tumors from Finland to evaluate if there 
are differences specific to the ethnic origin (East vs. West). Results showed for the first time a distinct 
genetic and epigenetic signature in the Egyptian CRC marked by high methylation of microsatellite 
7stable tumors associated with advanced stage, and low frequency of Wnt signaling activation,
suggesting a novel pathway.
DNA samples from FCCX families were studied with genome wide linkage analysis using 
microsatellite markers.  Selected genes from the linked areas were tested for possible mutations that 
could explain predisposition to a large number of colon adenomas and carcinomas seen in these 
families. Based on the results from the linkage analysis, a number of areas with tentative linkage were 
identified in family 20. We narrowed down these areas by additional microsatellite markers to found a 
mutation in the BMPR1A gene. Sequencing of an additional 17 FCCX families resulted in a BMPR1A 
mutation frequency of 2/18 families (11%). 
Clarification of the mechanisms of the differential tumor susceptibility in LS increases the 
understanding of gene and organ specific targets of MMR deficiency. While it is generally accepted 
that widespread MMR deficiency and consequent microsatellite instability (MSI) drives 
tumorigenesis in LS, the timing of molecular alterations is controversial. In particular, it is important 
to know that alterations may occur several years before cancer formation, at stages that are still 
histologically regarded as normal. Identification of molecular markers that could predict the risk of 
malignant transformation may be used to improve surveillance and cancer prevention in genetically 
predisposed individuals. 
Significant fractions of families with colorectal and/or endometrial cancer presently lack molecular 
definition altogether. Our findings expand the phenotypic spectrum of BMPR1A mutations and, for 
the first time, link FCCX families to the germline mutation of a specific gene. In particular, our 
observations encourage screening of additional families with FCCX for BMPR1A mutation, which is 
necessary in obtaining a reliable estimate of the share of BMPR1A-associated cases among all FCCX 
families worldwide. Clinically, the identification of predisposing mutations enables targeted cancer 
prevention in proven mutation carriers and thereby reduces cancer morbidity and mortality in the 
respective families. 
8REVIEW OF THE LITERATURE 
1.Cancer 
Cancer is one of the most common diseases around the world and directly or indirectly influences 
almost all of us. Even before Hippocrates, cancer has been investigated by a lot of scientists; naturally 
their belief of cancer formation varies a lot (Ballantyne 1988). Nowadays it is well known that cancer 
is a genetic disease, which means that a normal cell becomes malignant through alterations in its 
genome. This phenomenon is a multistep process, which usually starts many years before detectable 
symptoms (Renan 1993). Depending on what tissue type the cancer will emerge from, it will be called 
differently. Cancer that arises from epithelial surfaces is called a carcinoma and cancer that originates 
from glands or epithelial ducts is called an adenocarcinoma. If cancer emerges from soft tissues, it is 
called a sarcoma and if it emerges from nerve tissue it will be called a glioma 
(www.cancer.fi/tietoasyovasta/syopa/kudostyypit/). 
Globally, among men the most common cancers are lung, prostate, colorectum, stomach, liver, and 
oesophagus (http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#MEN). Among 
women the most frequent cancers in globally are: breast, cervix uteri, colorectum, lung, stomach, and 
endometrial (http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#WOMEN).  
Worldwide, over 7 million deaths occurred in 2008 and it has been estimated that in 2030 >10 million 
people will die because of cancer (http://www.who.int/mediacentre/factsheets/fs297/en/index.html).  
In Finland different cancer types are responsible for over 10 000 cancer deaths per year 
(http://www.cancerregistry.fi/stats/fin/vfin0004il.html). In table 1, the five most common cancer types 
in Finland in 2009 are listed. There are six phenomena that are mainly responsible for cancer 
formation. 
Table 1. The five most common cancer types
in Finland in year 2009. 
Cancer types Cases in 2009
Breast 4469
Colorectum 1255
Women Endometrial 808
Lung, trachea 691
Skin, non-melanoma 669
Prostate 4595
Lung, trachea 1676
Men Colorectum 1391
Skin, non-melanoma 713
Bladder, ureter, urethra 708
91.1 Capability to maintain own growth and anti growth factors  
Before a normal cell can turn from a dormant state to an active, proliferative state it seeks mitogenic 
growth signals or factors. Normal cells cannot proliferate without these positively acting components, 
called signaling molecules. Signals are transmitted into the cell across the cell membrane by binding 
to transmembrane receptors. Growth factors, cell external matrix components, and cell-cell adhesion 
molecules are included in to these signaling molecules (Hanahan and Weinberg 2000). 
Many of the oncogenes make cells independent of these signaling molecules in one way or another, so 
it is obvious that tumor cells regulate their own growth signals to survive. They liberate themselves 
from the needs of normal cell signaling, which originate from the microenvironment of the cell. This 
liberation from the reliance on external signaling molecules destroys critically important homeostatic 
factors, which normally act in different cell types and assure normal growth circumstances (Hanahan 
and Weinberg 2000).  
In normal tissue there are many antiproliferative signals that work constantly to keep up cellular 
homeostasis and quiescence. Two types of inhibitors belong to these antiproliferative signals: soluble 
growth inhibitors and inhibitors that are immobilized and embedded in the extracellular matrix and on 
surfaces of the nearby cells. There are two different mechanisms how antigrowth signals can stop 
proliferation. Firstly cells can transform from an active proliferative state to a quiescent state from 
which they can again became activate later on vie the extracellular signaling effect. Secondly, cells 
can permanently resale their proliferation potential by acquiring a postmitotic state (Hanahan and 
Weinberg 2000).   
Many aspects, which mediate normal cell response to avoiding proliferation signals, relate to the cell 
cycle, especially the transformation from the G1 state to the growth cycle state. Cells observe their 
external state during this phenomenon and based on these signals they decide to proliferate, stay still, 
or move to the preproliferation state. Cancer cells also have potential to switch off the expression of 
integrins and other cell adhesion molecules, which mediate antiproliferation signals (Hanahan and 
Weinberg 2000). 
1.2 Capability to avoid apoptosis and limitless replicative potential 
The apoptotic machinery is present in all human cells. When the apoptosis program is triggered via 
physiological signals, it leads to cell death in a very sophisticated manner (Wyllie et al., 1980). This 
phenomenon is completely missing from all kinds of malignant tumors and this is one of the 
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hallmarks of cancer (Hanahan and Weinberg 2000). Apoptotic machinery can be divided into two 
parts - sensors and effectors.  The sensors monitor intra- and extracellular environment for 
abnormality or normality, which affects whether cell should stay alive or die. These signals of the 
sensors regulate the other part of machinery, which function as effectors of programmed cell death 
(Lotem and Sachs 1996; Butt et al., 1999).    
Cell cultures suggest that in various normal human cells proliferation occurs usually 60-70 times 
before it ceases (Wyllie et al., 1980). Many or all of the normal human cells have intrinsic potential to 
restrict cell proliferation (Hanahan and Weinberg 2000). Cell proliferation restriction is missing in 
tumor cells, which have a phenotype of unlimited replicative potential. This undoubtedly is one of the 
driving forces of reaching the malignant state (Hayflick 1997). 
1.3 Capability to angiogenesis, to invade and metastasize 
When tissue is formed, new blood vessel formation – angiogenesis – is regulated very accurately 
(Hanahan and Weinberg 2000). The cells that suffer diverging proliferation lack the opportunity for 
angiogenesis, which prevents their ability of proliferation. In order to be able to grow, a tumor has to 
procure the ability of angiogenesis (Bouck et al., 1996; Hanahan and Folkman 1996; Folkman 1997). 
It  seems  that  tumors  activate  the  angiogenetic  “switch”  by  altering  the  balance  between  the  
contributor and antagonist (Hanahan and Folkman 1996). One common strategy for balance altering is 
varying gene transcription. Many tumors enhance VEGF and/or FGF-gene expression compared to 
normal tissue. The expression of some of the tumors antagonists such as thrombospondin-1 or β-
interferon decreases. Both of these above-mentioned changes occur for most of the tumors (Sighn et 
al., 1995, Volpert et al., 1997). 
Successful invasion deeper to the tissue is a prerequisite for cancer progression as well as (for most 
cancers) metastasis. Invasion and metastasizing are very complicated events and the genetics and 
biochemical mechanisms behind them are not very well known. It is known that invasion and 
metastasizing require at least external activation of cell proteases (Hanahan and Weinberg 2000). 
Cell-cell adhesionmolecules and integrins, which connect cells to their external material substrates, 
are known to be responsible for triggering invasion and metastasis (Aplin et al., 1998). 
In some stages of tumor formation, a couple of cells can detach from the original mass and travel to a 
distant site where they might form a new tumor mass. This process of forming new distant masses is 
called metastasizing and it is responsible for cancer deaths in approximately 90% of cases (Sporn 
1996). Metastasis is usually a very late form of tumorigenesis (Weigelt et al., 2005).  
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2. Cancer genetics 
Even though cancer is a complex disease, usually involving many environmental and nongenetic 
factors,  it  is  mainly  a  genetic  disease.  Mutation  rates  in  genes  vary  from  cancer  precursors  to  
malignant tumors. Approximately three to seven mutations in four to five different genes are needed 
for cancer formation, whereas in the cancer precursor stage perhaps only two mutations are needed 
(Vogelstein and Kinzler 1998). These mutations usually arise in tumor suppressor genes or 
oncogenes. Both of these genes are important for proliferation and determination of cell fate, as well 
as senescence, apoptosis and differentiation of the cell (Weinstein 2002).  
2.1 Oncogenes 
In order to grow tumor mass needs to have mutations in growth promoting genes, oncogenes. Proto-
oncogenes or oncogenes are one of the key players in tumorigenesis. Oncogene activation by mutation 
is strongly linked to carcinogenesis (Weinberg 1991). Oncogenes were discovered over 30 years ago 
and nowadays more than 100 oncogenes are known. The over-expressing effect of a mutation on an 
oncogene in a malignant tumor depends on the cell type in which it is expressed. Oncogene 
overexpression can cause apoptosis in one cell type, whereas in another cell type it can enhance cell 
growth (Vogelstein and Kinzler 1998; Weinstein 2000; Hanahan and Weinberg 2000). Once the 
oncogene has experienced a mutation, it is required for tumorigenesis as well as the maintenance of 
the malignant phenotype of the particular tumor at all times (Jain et al., 2002). 
2.2 Tumor suppressor genes 
Tumor suppressor genes (TSG) are genes that provide a cell with the capability to accept and process 
growth suppression signals from its environment. They are also key players in the intracellular 
signaling cascade. Tumor suppressor gene inactivation by mutation or methylation is linked to 
carcinogenesis (Weinberg 1991).  TSG controls versatile cellular activities; responses to cell cycle 
checkpoints, as well as perceiving and repairing of DNA damage. In addition, protein degradation and 
ubiquitination, tumor angiogenesis, cells movement and differentiation, cell definition and mitogenic 
signaling belong to TSGs duties (Sherr 2004). TSGs can be divided into gatekeepers and caretakers. 
The gatekeepers are genes that function actively in cell proliferation (Weinberg 2007). Mutations in 
caretaker genes frequently lead to the conversion from normal cells to neoplastic cells. The caretaker 
genes’ function is to maintain cell genome integrity (Levitt and Hickson 2002). 
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Knudson investigated retinoblastoma, which is a rare malignant childhood disease, and found that 
mutations inactivating both copies of a TSG affect the development of this disease. Nowadays it is 
known as Knudson’s two hit theory, (Fig. 1). In sporadic form of retinoblastoma, both copies of 
retinoblastoma-gene (RB1) are inactivated by a somatic mutation. In the familial form, the first 
mutation is inherited from one parent in the germline and the second inactivating mutation of the 
RB1-gene is acquired (Knudson 1971).   
There are different mechanisms by which a TSG (e.g. RB1) can be inactivated: point mutation 
typically affects the first allele. Another point mutation frequently inactivates the second allele. 
Additionally, mitotic recombination and chromosome loss can be behind inactivation of the second 
allele (Michor et al., 2005). Recent evidence suggests that either hit can also consist of an epigenetic 
change (Wajed et al., 2001). 
Familial Sporadic
First
mutation
(somatic) 
Second
mutation
(somatic)
One mutant Rb
allele
Two mutant Rb
alleles
Two mutant
Rb alleles
First
mutation
(germline)
Second
mutation
(somatic)
One mutant
Rb allele
Two wild-
type alleles
2.3 Genomic instability in cancer
Approximately 1.4x10-10 mutations occur in normal human cells in cell generation per basepair. In 
precancerous and cancerous cells, mutations occur multiple times of that observed in normal cells. 
Genomic instability is a driving force in tumorigenes (Charames and Bapat 2003). Tumorigenesis 
acquires many genetic alterations on a chromosome and/or gene or nucleotide level. The following 
facts highlight the importance of genomic instability in cancer: a) there are so many mutations in 
malignant tumors that only instability on the genome level can explain them b) hereditary instability 
Figure 1. Knudson’s two hit model of retinoblastoma occurrence (modified from Knudsson 1971).  
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leads to vulnerability to tumors in humans as well as model organisms c) some pathways that sustain 
genome maintenance are defective in tumors (Lengauer et al., 1998).  
Small alterations in DNA sequence can be described as one to a few nucleotide insertions, deletions, 
or substitutions. These alterations occur very rarely in cancers, but when they do occur it might cause 
a severe phenotype (Lengauer et al., 1998). Genomic instability can take the form of microsatellite 
instability (MIN or MSI) or chromosomal instability (CIN). Defects in the following repair systems 
have a major role in tumorigenesis: mismatch repair (MMR), base-excision repair (BER), nucleotide-
excision repair (NER), chromosomal segregation and recombinational repair; furthermore, CpG-
island methylation status affects genomic instability (Lengauer et al., 1998; Jones and Baylin 2002; 
Hoeijmakers 2001).  The DNA mismatch repair system is described in more detailed under the 
“Colorectal cancer” topic and CpG-island methylation under “Epigenetics in cancer”. 
2.3.1 Base-excision repair 
Mutations caused by cells’ internal metabolism, eg. reactive oxygen species, are repaired by base-
excision repair  (BER) (Colussi et al., 2002). The starting point for BER occurs through DNA 
glycosylases, which are a class of enzymes, which recognize chemically modified bases. A stable 8-
oxo-7, 8-dihydro-2’-deoxogyanosine (8-oxoG) is produced by DNA damage. Stable 8-oxoG mispairs 
with adenine lead to transversion mutations, eg. G:C to T:A  (Lindahl 2000). Oxidated guanine has 
highly mutagenic effects and E. coli studies have shown that mutY, mutM, and mutT are specific 
repair enzymes that protect against oxidated guanine. Humans have homologues for these enzymes: 
OGG1 protein for mutM, MYH protein for mutY, and MTH protein for mutT (Chen et al., 2002).
2.3.2 Nucleotide-excision repair 
Nucleotide-excision repair (NER) is needed to correct DNA damage caused by multiple exogenous 
mutagens. NER was first recognized for its role in skin cancer formation, in the context of xeroderma 
pigmentosum (XP) (Cleaver et al., 1968). XP patients’ skin fibroblasts are more sensitive to 
ultraviolet light than normal cells. Ultraviolet light (among other exogenous mutagens) induces 
covalent modifications to DNA and NER can correct these modifications (Bootsma et al., 1998).   
2.3.3 Microsatellite instability  
A defect in the MMR pathway, typically a mutation in one of the MMR gene (see Fig. 6), causes 
microsatellite instability (MSI). Microsatellites are repetitive sequences that are scattered throughout 
the whole genome. In individuals microsatellites are polymorphic, but in each person and tissue they 
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are uniquely similar in length (Boland and Goel 2010). Microsatellites may consist of mono, di, tri, or 
tetra, - nucleotide repeats. Blake et al. (2001) observed mutations in dinucleotide sequences from 
CRC samples. These mutations were deletions in CA repeat sequences and they launched the term 
microsatellite instability (Blake et al., 2001). MSI represents a unique pathway for carcinogenesis 
(Thibodeau et al., 1993).
2.3.4 Chromosomal instability 
Increased loss or accumulation of chromosomal material which leads to polyploidy or aneuploidy can 
be described as chromosomal instability (CIN) ( Rowan et al., 2000; Abdel–Rahman et al., 2001).  
There are so called “CIN-genes” identified in humans, which include: BRCA1 and BRCA2, CDC4,
MAD2, and BUB (Li and Benenzra 1996; Milner et al., 1997; Pangilinan et al., 1997; Yarden et al., 
2002; Rajagopalan et al., 2004). For example: BRCA1 and BRCA2 function in DNA recombination 
and repair, transcription, and cell cycle checkpoint control (Milner et al., 1997; Pangilinan et al.,
1997). CIN genes can be classified into classes I to III. If one allele of class I gene, e.g. MAD2 is lost 
or mutated it affects CIN. BUB1 gene caused CIN only when another  allele  is  mutated.  Class  I  and 
class II CIN genes are “single hit” genes, meaning that a single mutation is enough to cause CIN. 
BRCA1 and BRCA2 are CIN III genes and to trigger CIN they need to have a mutation in both of the 
alleles.  CIN can occur at any time during carcinogenesis and it can lead not only to an aneuploidy 
(imbalance of chromosome number) but also to the loss of heterozygosity (LOH) (Michor et al.,
2005).
2.3.5 Loss of heterozygosity 
LOH can cause the inactivation of tumor suppressor genes (Michor et al., 2005) by somatic loss of 
chromosomal material, ranging from a chromosome sub band to the whole chromosome. LOH can be 
measured by comparing the tumor tissue to the normal tissue (e.g. blood leukocytes) from the same 
individual by different methods (e.g. using fragment analysis). If LOH is present in a particular tumor, 
then one allele is missing or has decreased in intensity. These missing or attenuated alleles frequently 
contain tumor suppressor genes. In many common cancers, multiple regions of chromosomal losses 
have been identified by LOH analysis (Osborne and Hamshere 2000). Still the number of TSGs that 
have been recognized based on LOH remains low; if it is required that a somatic mutation must be 
seen in the remaining allele (Fero et al., 1998). 
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2.4 Methods to identify new cancer predisposition genes 
Many cancer related diseases and syndromes have been described, but the predisposing mutations in 
one or several genes that affect the majority of these syndromes are still unknown.  To identify a new 
gene would be a great breakthrough not only for a scientist, but primarily for a patient and families 
who suffer from the disease.   Nowadays genome wide linkage analysis are usually performed with 
SNP (single nucleotide polymorphism) arrays (Roberts et al., 2010), but other screening methods are 
also  useful,  such  as  a  microsatellite  marker  analysis  (Nieminen  et al., 2011) and sib-pair linkage 
(Daley et al., 2008). All methods require fine mapping of the genome area, after getting the linkage 
results. After the fine mapping of a relevant area, one needs to choose the best candidate genes and 
sequence them through to find a mutation. Also, next generation sequencing can be used to identify 
new predisposing genes behind cancer or other diseases.  
2.4.1 Linkage analysis 
Linkage analysis is a very efficient method to identify new predisposing genes. The purpose of 
linkage analysis is to identify a common area of the genome, which has been passed down to next 
generations with multiple individuals. The advantage of linkage analysis is its usefulness to screen the 
whole genome with a set of different markers, which makes it a hypothesis-free method. This method 
is suitable for autosomal dominant inheritance, because usually there is a good correlation between 
the phenotype and genotype of a single gene (Gulcher et al., 2001).   
2.4.2 Sib-pair study 
By studying affected sib-pairs it is possible to identify shared genome areas, which are combined 
more frequently than would be assumed by chance alone (Kerber et al., 2008). Daley et al. (2008) 
studied 194 mainly colon neoplasia kindred by genome-wide linkage analysis using dinucleotide 
markers.  They studied not only affected, but also unaffected and discordant sib-pairs to identify 
common linkage region/s of the genome. Families were divided for five different subgroups based on 
clinical information: severe histopathology of colon, young age at CRC onset, few colon polyps, 
colon or breast cancer, and multiple cancers. Results pointed out five different chromosome areas for 
potential linkage. They concluded that the inclusion of unaffected sib-pairs and dividing the material 
into different subphenotypes increased the power of analysis when searching for colon cancer 
predisposition genes (Daley et al., 2008). 
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2.4.3 Genome-wide association studies 
Genome-wide association (GWA) studies are the most widely used method to identify new cancer 
predisposing genes these days. In this method, allele frequencies are compared between affected 
individuals and healthy ones (controls) (Stadler et al., 2010). Even though DNA from different 
individuals is almost identical (99.9%), some variations exists (Kruglyak et al., 2001), and SNPs 
represent a varying part of the genome. By assessing how often particular SNPs occur in affected 
individuals, one may be able to identify what genomic region/s associate with a disease. It is thus 
possible to identify a disease- associated SNP by statistical estimate (Stadler et al., 2010). This 
method is suitable for common diseases, where the inheritance pattern is not very clear (Lander and 
Kruglyak 1995; Risch and Merikangas 1996).  
DNA from several thousands of controls (healthy individuals) and cases (affected individuals) are 
genotyped by e.g. microarray chips. Microarray chips can detect SNPs from the genome, from each of 
the individuals. Data from the microarray are normalized and quality checked, and statistical methods 
are  used to calculate  associations between a SNP and disease.  If  a  disease-associated SNP is  found,  
the result is confirmed with larger set of cases and controls. The confirming array contains only the 
SNPs of interest (from the first run). Despite the wide use of GWAS, the association for a particular 
phenotype (i.e. cancer) is relatively rare (Stadler et al., 2010). 
Jass syndrome was found to be linked to chromosome 2q32.2-q33.3 using SNP arrays. Jass syndrome 
is a serrated familial neoplasia associated with high risk of colon cancer. Roberts et al. (2010) 
investigated families with this syndrome by using Affymetrix GeneChip Human Mapping 10 K SNP 
Array to identify linked loci. They investigated linkage from a large family with autosomally 
dominantly inherited predisposition to the Jass phenotype. Before analysis can be performed, certain 
parameters are needed for the calculation of the results for parametric linkage. Roberts et al. (2010) 
assumed an autosomal dominant mode of inheritance, with 60% penetrance and 0.001 frequency of a 
disease allele and 10% rate of phenocopy.  They got a logarithm of the odds (lod) score of 1.36. After 
finemapping and haplotype analysis of the linked area, they found five potential candidate genes. 
Despite the sequencing of those genes, a mutation was not found (Roberts et al., 2010). 
2.4.4 Next-generation sequencing 
Next-generation sequencing (NGS) is a relative new method to identify cancer associated mutations. 
The method detects point mutations, including base substitutions and small insertions or deletions 
(indels). Additionally, choromosomal aberrations, like copy number changes can be recognized (Goh 
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et al., 2011). NGS produces millions of parallel sequence reads (which are relatively short, 35-250 bp) 
from fragmented DNA libraries, which means that an entire genome will be sequenced in one or two 
runs. Fragments are prepared for sequencing by ligating specific adapter oligos to both ends of each 
DNA fragment. Benefits of this method are that it requires small amounts of DNA and produces large 
amounts of data (Mardis 2007). 
3. Epigenetics in cancer 
The word “epigenetic” means modification in gene function which is not caused by changes in the 
DNA sequence (Bird 2002).  Altered methylation of CpG island promoters in cancer cells is one of 
the most important and widely studied fields in last 10-20 years in cancer research. There are two 
main categories in altered methylation: hypomethylation and hypermethylation (Feinberg and Tycko 
2004), (Feinberg et al., 2006). Additionally, histone modification via histone acetylation or 
methylation (Verdone et al., 2005) and RNA interference participate in DNA methylation in human 
cells (Morris et al., 2004).  
In vertebrates, methylation takes place mainly at the cytosines that precede guanines (Bird 1986). A 
large part of the human genome is CpG depleted and this is thought to be because of a large amount 
of mutations from CpG to the TpG/CpA form (Sved and Bird 1990; Chan et al., 2001). CpG islands in
CpG promoter regions, which are protected against DNA methylation, make an exception to the 
previous rule.  Methylation occurs commonly in CpG sites that may be located in gene-coding or non-
coding areas (Warnecke and Clark 1999).  
CpG sites or islands are regions in genome spanning approximately 500 bp to few kbs (Gardiner-
Garden and Frommer 1987; Takai and Jones 2002). They are located in the proximal part of the 
promoter region of ~ 75 % of human genes and the majority of them are unmethylated at all 
developmental stages and in all tissue types (Bird 1986; Goll and Bestor 2005). The majority of CpG 
dinucleotides, which are located outside of CpG sites are methylated, particularly those that are 
located in repetitive DNA elements. Approximately 45 % of the genome consists of repeat DNA 
elements and the majority of 5-methylcytosines (5mCs) exists in such regions. The primary function 
of DNA methylation is to prevent the activity of the repeated DNA. (Yoder et al., 1997). 
3.1 Hypomethylation 
Hypomethylation of DNA has a mechanistic role. Hypo-or demethylation can lead to gene activation 
(Strichman-Almashanu et al., 2002; Jones 2005).  The cancer cell genome and tissues are commonly 
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hypomethylated as compared to DNA from normal tissue. This finding was made when a total level of 
5mC was measured (Gama-Sosa et al., 1983; Goelz et al., 1985). Usually hypomethylation was found 
to be manifested in single-copy genes (Gama-Sosa et al., 1983), eg. proto-oncogenes. H-ras
oncogene´s HhaI and HpaII sites were found to be hypomethylated in lung and colon cancers 
(Feinberg and Vogelstein 1983). H-ras´s HpaII sites are commonly hypomethylated, located in the 
3 r´egion, and associated with allelic loss in nonsmall cell lung cancer (Vachtenheim et al., 1994).
Sato et al. (2003) discovered that 7 genes out of 19 showed no expression in normal pancreatic tissue, 
compared to pancreatic cancer tissue, where these 7 genes were overexpressed. These same 7 genes 
were hypomethylated in primary pancreatic cancers, and in pancreatic cancer cell lines. As a 
consequence, hypomethylation is associated with the instability of chromosomes and loss of 
imprinting, and is strongly linked to carcinogenesis (Eden et al., 2003; Gaudet et al., 2003; Holm et
al., 2005; Cui et al., 2003; Sakatani et al., 2005). 
3.2 Hypermethylation 
Gene silencing is associated with promoter hypermethylation of CpG islands of genes (Jones 2005). 
In sporadic cancers almost half of the tumor-suppressor genes can be silenced by hypermethylation 
(Baylin and Herman 2000). It is widely seen, that e.g. Wnt-signalling and APC genes are 
hypermethylated in colon cancer (Hiltunen et al., 1997; Suzuki et al., 2004), whereas in melanoma the 
hypermethylation of CDKN2A/p16 gene is a common feature (Gonzalez-Zulueta et al., 1995). 
Hypermethylation occurs by inhibiting transcription factor binding or via the activation of methylated 
DNA binding proteins (MBD proteins), or the modification of chromatin.  The MBD protein family 
includes several different proteins, of which MeCP2 was the first known member. MeCP2 is able to 
bind to a single CpG dinucleotide (which is methylated), irrespective of sequence context (Lewis et 
al., 1992). It can prevent transcription by recruiting Sin3 through its transcriptional silencing domain, 
which is connected to histone deacetylases, or by attaching to methylated DNA. When occurring in 
cancer cells, hypermethylation has to have a temporal connection between methylation and 
acetylation of associated histones, CpG methylation, and MBD binding proteins (Stirzaker et al., 
2004).
3.2.1 CpG island methylator phenotype 
CpG island methylator phenotype (CIMP) means that many CpG islands of tumor suppressor genes or 
DNA repair genes are methylated. CIMP can epigenetically silence the expression of TSGs. (Wong et 
al., 2007). Methylation of multiple TSGs throughout the genome is a frequent event in many cancers 
but especially in sporadic colorectal cancer (Toyota et al., 1999a; Weisenberger et al., 2006; 
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Samowitz et al., 2005). CIMP + phenotype associates frequently with MSI, BRAF V600E mutation 
and MLH1 DNA repair gene methylation (Toyota et al., 1999a; Weisenberger et al., 2006; Samowitz 
et al.,2005; Ogino et al., 2007). It has been suggested that CIMP + phenotype is combined also in 
sporadic colorectal cancer with no CIN or MSI (Goel et al., 2007). This suggestion implies that there 
are two self-sufficient mechanisms of epigenetic and genetic instability in sporadic colorectal cancer 
tumorigenesis (Cheng et al., 2008). 
3.3 Methods to study methylation 
In the tumor-cell heterogeneity conference, which was held 1982 at John Hopkins, Bert Vogelstein 
and Andy Feinberg wondered what factor affects various mutations and plasticity in some tumors. 
They began investigating the differences between normal and tumor tissue. By Southern-blotting 
analyses they discovered that an integral part of CpGs were unmethylated in tumors whereas in 
normal cells the same CpGs were methylated (Feinberg and Vogelstein 1983). Similar findings were 
made by Ehrlich and colleagues, who discovered that the 5-methylcytosine content was widely 
decreased in human tumors (Gama-Sosa et al., 1983). Furthermore, altered DNA methylation was 
found from normal and malignant colon tissue (Goelz et al., 1985), colon cancer precursor adenomas 
(Feinberg et al., 1988), and recently also from endometrial cancer precursor lesions (Nieminen et al., 
2009).
There are several different methods and applications to study methylation, and the principles and 
basics of each method are listed in table 2.  Jordá and Peinado (2010) describe three different 
strategies on which the detection of DNA methylation can be based:  (1) Methylation-sensitive or 
insensitive restriction enzyme digestion of DNA, (2) DNA chemical modification by bisulphite 
treatment, and (3) antibody purification of methylated sites of the genome. 
Additionally, next-generation sequencing techniques are useful to study methylation.  Over 90% of all 
human CpGs can be targeted by using epigenome-wide maps (Lister et al., 2009). To identify 
methylated areas with a direct method, genomic DNA is treated with bisulfite and target regions are 
amplified by PCR. After PCR, all fragments are sequenced by NGS in one run. In an indirect method, 
the methyl binding proteins or an anti-5mC antibody are used to precipitate the DNA fragments that 
contain methylated cytosines. Methylated regions of 100-200 bp in length can be analyzed by indirect 
methods (Schweiger et al., 2011). 
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Table 2. Methods to study methylation and their principles. Methods are divided into the measuring of 5-methyl cytosine, sequencing, and  genome-wide
methods (Modified from Jorda and Peinado 2010).
Analysis Principle Detector Separating capacity References
Measuring  overall  5-methyl cytosines
MALDI-TOF mass
spectrometry Bisulphite treatment Mass spectrometry
Based on differing shifts 
on (mass) daltons Ehrich et al ., 2005
High performance liquid
chromatography (HPLC) HPLC separation Absorbance 5-mC genomic content Eick et al ., 1983
High performance capillary
electrophoresis (HPCE) HPLC separation Absorbance 5-mC genomic content Fraga et al ., 2000
Methods that are based on PCR and/or sequencing
Amplification by PCR
Amplification after MS-
restriction enzyme digestion PCR
One recognition site for the 
enzyme that has been used Kutueva et al ., 1996
Bisulfite sequencing Bisulphite treatment PCR Sequencing
Frommer et al ., 1992;   
Clark et al.,1994
Southern blot
MS-restriction enzyme
digestion Hybridization Hybridization Gounari et al ., 1987
PyroMeth Bisulphite treatment Pyrosequencing Every CpG of the amplicon Uhlmann et al ., 2002
MS-PCR Bisulphite treatment PCR Primer contains few CpGs Herman et al ., 1996
MethyLight Assay Bisulphite treatment Fluorescence RT-PCR Primer contains few CpGs Eads et al ., 2000
Headloop PCR Bisulphite treatment PCR Primer contains few CpGs Rand et al ., 2005
Melting curves Bisulphite treatment Fluorescence RT-PCR Worm et al ., 2001
Cobra
Bisulphite treatment +
MS restriction enzyme PCR
One regocnition site for the
 enzyme that have been used Xiong and Laird, 1997
MS-SnuPE Bisulphite treatment PCR One CpG site
Gonzalgo
 and Jones, 2002
MS-SSCA Bisulphite treatment SSCA Amplicons average methylation Bianco et al ., 1999
MS-MLPA
MS-restriction enzyme
digestion PCR
Probes contain restriction 
site for HhaI MRC-Holland 2011
Genome-wide methods
Restriction landmark
genomic scanning
MS-restriction enzyme
digestion 2D-electrophoresis
Recognition sites of the 
RE used within the genome Hatada et al ., 1991
AP-MS-PCR
MS-restriction enzyme
digestion Southern blot
Recognition sites of the 
RE used within the genome Gonzalgo et al ., 1997
MCA
MS-restriction enzyme
digestion RDA
Recognition sites of the 
RE used within the genome Toyota et al ., 1999 b
AIMS
MS-restriction enzyme
digestion Fingerprinting
Recognition sites of the 
RE used within the genome Frigola et al ., 2002
DMH
MS-restriction enzyme 
digestion Microarray
Recognition sites of the 
RE used within the genome Huang et al ., 1999
MSO Bisulfite treatment Microarray Few CpGs inside the probes Gitan et al ., 2002
MeDIP-chip 5-mC antibody Microarray
Mean methylation of the 
MeDIP purified sequences
 and hybridized on the array Weber et al ., 2005
Illumina Infinium Human
 Methylation 27 bead chip Bisulfite treatment Fluorometer One CpG site Fouse et al., 2010
Abbreviations: MS, methylation sensitive; RE, restriction enzyme; 5mC, 5-methyl cytosine; MALDI-TOF, Matrix-assisted laser desorption ionization time-of-flight;
MS-PCR, methylation sensitive-polymerase chain reaction; Cobra, COmbined Bisulfite Restriction Analysis; MSO, methylation specific oligonucleotide
MS-SnuPE, methylation sensitive-single nucleotide primer extension; SSCA, single conformational analysis; Me-DIP-chip, methyl-DNA immunoprecipitation chip
MS-MLPA, methylation sensitive-multiplex ligation dependent probe assay; AP-MS-PCR, arbitrarily primed methylation-sensitive-PCR; 
MCA, methylated CpG island amplification; AIMS, amplification of intermethylated sites; DMH, differential methylation hybridization;
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4. Colorectal cancer  
Colon cancer (CRC) is the third most common cancer in Finland. New cases arise annually 
approximately 750 in men and more than 800 in females according to the Finnish Cancer Registry 
(http://www.cancerregistry.fi/stats/fin/vfin0021i0.html, 2008). Worldwide, the amount of new 
colorectal cancer cases is estimated to grow annually with over 660000 and 570000 new cases in 
males  and  females,  respectively.  Estimations  have  been  made  that  CRC  causes  more  than  600  000  
deaths worldwide every year (International Agency for research on Cancer, GLOBOCAN 2008, 
http://globocan.iarc.fr/factsheets/cancers/colorectal.asp). The majority (90%) of CRC diagnoses are 
made for people that are 50 years of age or over (Altekruse et al., 2010)
4.1 Epidemiology and ethnic influences 
CRC occurs more frequently in developed (Western) than undeveloped countries (Parkin et al., 1992). 
One reason might be Western style food, which is rich in red meat and fat and poor in fiber. People 
from Western countries suffer from diabetes mellitus, are more obese, and many of them use a lot of 
alcohol;  all  of  these  are  presumable  risk  factors  for  CRC  (Weitz  et al., 2005).  In the middle-east 
countries CRC is a disease with relatively young age at onset, mucinous histology, and rectal location, 
(Soliman et al.,1997; Abou-Zeid et al., 2002;  Dajani et al., 1980; Al-Jaberi et al., 1997). Differences 
of  CRC pathways are shown in figure 16,  page 64.  Prognosis  for  CRC varies  for  worldwide;  in  the 
USA the  5-year  survival  rate  exceeds  60  %,  whereas  in  undeveloped  countries  it  is  less  than  40  % 
(Stewart and Kleihues 2003). 
4.2 Sporadic colorectal cancer 
Approximately 76% of all CRCs are sporadic, occurring by chance or due to environmental factors, 
and 24% have some sort of hereditary background, (Fig. 2) (Lynch et al., 2009). Additional risk 
factors, other than age, for sporadic CRC are male gender, cholecystectomy, and hormonal factors, 
like older age for first pregnancy and early menopause (Weitz et al., 2005). 
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As early as 1871, Professor Theodor Billroth discovered that colorectal tumors are of mucosal origin 
and therefore, represent a local disease (Billroth 1871). Since then many researchers have traced colon 
tumor carcinogenesis. In 1990 Fearon & Vogelstein proposed a mutational theory, which suggests that 
colon neoplasms have monoclonal composition. The polyclonal theory suggests that aberrant 
differentiation or field effects are responsible for colon neoplasm. Normal colon tissue (epithelium) is 
polyclonal, because it arises from several epithelial stem cells.  Adenomas emerge from a single 
pocket of epithelial stem cells. (Ponder and Wilkinson 1986). For a normal cell to proceed from a 
colon adenoma stage to a carcinoma, seven distinct genetic changes are required as suggested by 
Kinzler & Vogelstein 1996. In sporadic colorectal tumorigenesis, these genetic changes usually arise 
in K-ras, APC, TP53, and DCC genes. (Fearon and Vogelstein 1990). Functions of these genes are 
depicted in table 3. 
Figure 2. Approximate proportion of sporadic, familial and hereditary colorectal cancers. Approximately 76 % of 
the CRCs are of sporadic origin. Approximately 14 % of CRCs show some familial clustering and less than 10% 
are hereditary (Lynch et al., 2009; de la Chapelle 2004; Lynch and de la Chapelle 2003, Lynch and de la Chapelle 
1999). The hereditary forms, Lynch syndrome, FAP, FCCX, AFAP, PJS, and other  hamartomatous polyposis 
syndromes will be described in more detail under Hereditary component in colorectal cancer.  
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Table 3. Functions of the most common known CRC related genes
Gene Function Origin of CRC Reference
APC
Regulates normal epitelial cell progression 
to adenoma to carcinoma Hereditary and sporadic
Kinzler and
Vogelstein 1996
DCC
Cell growth controlling, differentiation, and 
metastases development Sporadic Cho  et al ., 1995
K-ras
G-protein related mediated signal 
transduction Sporadic Bos 1989
TP16
Controls cell growth and proliferation in 
the G1 phase of cell cycle in a negative 
manner and regulates the angionetic 
switch
Sporadic
Sharpless 2005;
Alhaja et al .,
2004
TP53
Associates the transcription of the genes 
that modulates senescence, the cell 
cycle, and apoptosis
Sporadic and hereditary Jin and Levine,
2001
MLH1
Repairs DNA mismatches during 
replication Hereditary and sporadic
Abdel-Rahman 
et al ., 2006
MSH2
Repairs DNA mismatches during 
replication Hereditary
Abdel-Rahman 
et al ., 2006
MSH6
Repairs DNA mismatches during 
replication Hereditary
Abdel-Rahman 
et a ., 2006
PMS2
Repairs DNA mismatches during 
replication Hereditary
Abdel-Rahman 
et al ., 2006
Besides the basic adenoma-carcinoma pathway, there are other pathways that contribute to colon 
carcinogenesis. One such pathway is the caretaker and gatekeeper pathway (Kinzler and Vogelstein 
1997). Approximately 85% of sporadic CRC occurs by the gatekeeper pathway, which is also 
responsible for FAP, through a mutation in the tumor suppressor gene APC, see figure 16, page 62. 
Other pathways exist as well, like the serrated adenoma pathway, flat adenoma pathway, and 
inflammatory bovel disease pathway (Krok et al., 2004; Jass et al., 2002; Soetikno et al., 2003; 
Itzkowitz et al., 2004).  
MSI is a very frequent event in sporadic CRC, and around 15 % of all CRCs have MSI (Popat et al.,
2005; Ward et al., 2001). Patients with MSI CRCs have better prognosis than those with 
microsatellite-stable (MSS) CRCs (Sinicrope et al., 2006). Silencing of MLH1 or PMS2 protein 
expression is the major cause of MSI in sporadic CRC (Kane et al., 1997). Additionally, the biallelic 
methylation of the MLH1 promoter (Veigl et al., 1998) and a mutation in the BRAF gene participate 
in sporadic MSI CRC development (Wang et al., 2003), see figure 16, page 62. 
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4.3 Hereditary component in colorectal cancer 
Hereditary CRC occurs at a younger age (~ 45 years) when compared to sporadic CRC (~70 years) 
(Lynch and de la Chapelle 1999). Hereditary colon cancers can be classified based on genetic, 
pathological, and clinical findings. Lynch syndrome may represent the most common form of 
hereditary colon cancer (Lynch et al., 2009; de la Chapelle 2004; Lynch and de la Chapelle 2003; 
Lynch and de la Chapelle 1999) and is described in a separate section below (p. 27). Hereditary CRC 
syndromes, other than Lynch syndrome, include among others, familial adenomatous polyposis and 
hamartomatous polyposis syndromes and their subtypes (Jasperson et al., 2010). Syndromes and their 
predisposing genes are depicted in figure 3.  
Familial adenomatous polyposis syndrome (FAP) is the second most common after Lynch syndrome.   
FAP individuals suffer from even hundreds or thousands of colon adenomas since early adulthood and 
if untreated, CRC develops.  The average age at onset of CRC is 39 years. A less severe form of this 
disease is attenuated FAP (AFAP), where individuals suffer from much fewer colon adenomas (0-
100+) and the age at onset is higher. Both of these above mentioned syndromes are caused by a 
germline mutation in the APC gene (Burt et al., 2004).  
MUTYH-associated  polyposis  (MAP)  syndrome  resembles  attenuated  FAP  and  it  can  be  associated  
with numerous polyps in an individual’s colorectum, which also leads to an increased risk of CRC. 
This syndrome is produced by biallelic mutations in the MY, or better known as the MUTYH, gene 
(Lubbe et al., 2009). The age at onset of CRC in MAP is around 40 years, although younger age at 
onset is also seen (Cleary et al., 2009). 
Hamartomatous polyposis conditions include Peutz-Jeghers- and Juvenile polyposis syndromes. Both 
of them cause increase the risk for CRC or other malignancies as well (Schreibman et al., 2005). 
Peutz-Jeghers syndrome (PJS) is caused by germline mutations in LKB1 (also  known  as  STK11),
which belongs to serine-threonine protein kinases (Hemminki et al., 1998; Jenne et al., 1998).  PJS 
diagnosis can be made when a patient meets two of the following three features: hamartomatous 
polyps in the small intestine, mucocutaneous hyperpigmentation, and a family history. The first 
symptoms of PJS usually arise in early teenage, including gastro-intestinal (GI) bleeding, small bowel 
obstruction, and intussusceptions (Gammon et al., 2009).  
Juvenile polyposis syndrome (JPS) causes appearance of many juvenile polyps frequently in the 
colon, but also in the small bowel, stomach, and duodenum (Brosens et al., 2007). JPS is caused by a 
germline mutation in the BMPR1A or SMAD4 gene and defects in these genes account for equal parts 
of JPS, approximately in 20 % of cases (Zbuk and Eng 2007). In the study by Brosens et al. (2007), 
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patients’ mean age at onset in JPS was approximately 44 years, whereas one case was diagnosed as 
early  as  30  years.  JPS  diagnosis  can  be  made  when  a  patient  meets  the  following  criteria:  ~  5  
colorectum associated juvenile polyps, juvenile polyps all over the GI tract, and whatever number of 
juvenile polyps in an individual who has a positive family history of these particular polyps 
(Giardiello et al., 1991). 
All of these above mentioned syndromes are inherited in an autosomal-dominant manner except 
MAP, which is inherited as an autosomal-recessive. A common feature also for these syndromes is 
that  they  affect  the  increased  risk  ratio  not  only  for  CRC,  but  other  organ  malignancies  as  well.  
Individuals suffering from FAP syndrome have 100 % lifetime risk of CRC, whereas in attenuated 
FAP the risk is 70%. In MAP individuals the lifetime risk for CRC is 80%, whereas in both PJS and 
JPS an individual’s lifetime risk for CRC is 39% (Jasperson et al., 2010). 
Colon Cancer Syndromes
Polyposis Syndromes Familial Nonpolyposis Colon Cancer Syndromes
Other Types of Adenomatous Polyposis
-Mutation in MYH gene
Hamartomatous Polyposis Syndromes
Peutz-Jeughers Syndrome
-Mutation in LKB1 (STK11) gene
Juvenile Polyposis Syndrome
-Mutations mainly in SMAD4 or
BMPR1A genes
Familial Adenomatous Polyposis
-Classic or Attenuated
Lynch Syndrome
-Germline mutations in 
DNA Mismatch repair genes
-MLH1
-MSH2
-MSH6
-PMS2
Familial Colorectal
Cancer Type X 
- No mutations in 
DNA Mismatch repair genes
-Mutated genes mostly unknown
-Mutation in APC gene
Figure 3. Scheme of colon cancer syndromes, which can be divided into polyposis syndromes and 
familial nonpolyposis syndromes. Polyposis syndromes include FAP, other types of adenomatous 
polyposis syndromes, and hamartomatous polyposis syndromes. Familial nonpolyposis colon cancer 
syndromes are divided into Lynch syndrome and familial colon cancer type X, FCCX (Modified from 
Lindor et al. 2005).  
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5. Hereditary non-polyposis colorectal cancer (HNPCC) 
HNPCC is an autosomally dominantly inherited disorder. It accounts for approximately 3-5 % of all 
CRCs (Mecklin 1987; Scapoli et al., 1994; Rodriquez-Bigas et al., 1997; Aaltonen et al., 1998, Lynch 
et al., 2009).  The  average  age  of  CRC  onset  in  HNPCC  is  approximately  20  years  earlier  than  
sporadic colon cancer. The age of the patients is approximately 44 years at the time of the CRC 
diagnosis (Jass et al., 1994). The lifetime risk of having colorectal cancer is very high, approximately 
70-80%, among HNPCC individuals (Scapoli et al., 1994; Vasen et al., 1996). Among males the risk 
to develop CRC is  80 %, which is  higher  when compared to that  of  females (40%) (Mitchell  et al., 
2002).  Tumors tend to arise on the right side of the colon for a majority of the cases (60-80%), and 
multiple tumors in the same individual are frequent. Villous adenomas are the most common 
precancerous lesions in the colorectum of HNPCC patients. Poorly differentiated colon carcinomas 
are frequent; despite the fact that the survival rate is better than in sporadic colon cancer cases (Gryfe 
et al., 2000).  
HNPCC was first described a hundred years ago (Warthin 1913). Before the genetic basis of the 
syndrome became known, an international collaborative group of researchers set up the Amsterdam 
criteria (AC) I and II, to better define this disease (Vasen et al., 1991; Vasen et al., 1999), (Table 4). 
For screening purposes, the revised Bethesda Guidelines were set up by Umar et al. (2004), (Table 5). 
When the human MMR genes were identified in the 1990s, it became possible to divide HNPCC into 
two separate categories, namely Lynch syndrome, in which MMR gene mutations are present, and 
FCCX, in which such mutations are absent (see Fig. 3). FCCX will be described in more detail in a 
separate section below (p. 29).  
Table 4. Amsterdam criteria I and II.
I II
At least three relatives should be diagnosed with CRC 
and all the below mention criteria should be present
At least three relatives should be diagnosed with 
HNPCC-related cancer (CRC, EC, small bowel, 
ureter, renal pelvis)
One relative should be a first-degree the other two One relative should be a first-degree relative the other 
Affection of two succesive generations Two successive generations should be affected
At least one CRC at young age of onset (<50 years) At least one should be diagnosed (<50 years)
Exlusion of familial adenomatous polyposis FAP CRC cases should be excluded
Tumor should be pathologically verified Tumor should be pathologically verified
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Table 5. Revised Bethesda (B1-B5) Guidelines
B1 CRC diagnosed before 50 years of age
B2 Extracolonic LS tumors or metachronous or synchronous CRC diagnosed at any age
B3 MSI-High CRC diagnosed <60 years of age
B4 CRC diagnosed in at least one first degree relative, with LS related cancer, of which one diagnosed < 50 years of age
B5 CRC diagnosed in at least two first or second degree relatives, with LS related tumor, regardless of age
5.1 Lynch syndrome (LS) 
As described above, LS is inherited in an autosomal dominant manner and cancer is diagnosed quite 
young (< 50 years). Many family members suffer from CRC or LS related extra colonic cancer and 
the occurrence of multiple primary LS-tumors in one person is also seen (Lynch et al., 2009).  Lynch 
syndrome- related extra colonic cancers may arise in the endometrium, urinary tract, brain, kidney, 
and gastrointestinal areas (Aarnio et al., 1999). Lynch syndrome-related colon cancer usually has a 
good prognosis (Vasen et al., 1991; Popat et al., 2005).  
Lynch syndrome is caused by a mutation in one of the MMR genes, which leads to a defect in the 
MMR machinery, see figure 6. MMR genes that are defective in Lynch syndrome are MLH1, MSH2,
MSH6 and PMS2 (Abdel-Rahman et al., 2006). Almost half of the mutations occur in the MLH1 gene 
and MSH2 gene mutations account for ~40% of cases. Mutations in the MSH6 gene are seen in less 
than 10 % and PMS2 mutations  account  for  less  than  2  %  of  all  cases  (Lynch  and  de  la  Chapelle  
2003). A mutation in the MSH2 gene is more often behind extracolonic cancer occurrence than a 
mutation in MLH1 (Eng et al., 2001; Mueller-Koch et al., 2005). Mutations in the MSH6 gene are 
connected especially to endometrial cancer. Overall, the atypical LS phenotype, involving cancers 
other than CRC, is more common in MSH6 mutation carriers than any other MMR gene mutation 
carriers (Jacob and Praz 2002; Buttin et al., 2004). PMS2 mutations may be more common in LS than 
originally thought (Senter et al., 2008).  
MSI testing is recommended to a person, when CRC tumors have a Crohn´s disease-like lymphocytic 
response, poor differentiation with mucinous, or signet ring pathology of the cells or infiltrating 
lymphocytes (Jass et al., 1994; Jass et al., 2007). BAT 25, BAT26 (mononucleotide markers), D2S123,
D5S346 and D17S250 (dinucleotide markers) are so called Bethesda panel markers that are widely 
used to detect MSI in Lynch syndrome patients. When two or more of the Bethesda panel markers 
show instability it can be classified as MSI-High (MSI-H). Instability is defined as an extra allele/s in 
a tumor’s DNA compared to matching normal DNA. MSI is very common in LS, especially in CRC 
(Kane et al., 1997; Cunningham et al., 1998; Marcus et al., 1999). 
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5.1.1 Tumor spectrum in LS 
Even though colorectal and endometrial cancers are the most prevailing cancers among Lynch 
syndrome individuals, many other less prevalent cancer types occur in excess in this syndrome, 
including urinary tract cancers, brain, kidney, and stomach cancers (Aarnio et al., 1999). Breast 
cancer might also be part of this syndrome, but more evidence is needed (Vasen et al., 2001a; Boyd et
al., 1999).  
Gastric cancer is the third most common cancer in LS individuals after CRC and endometrial cancer. 
The gastric cancer risk is highest between 50 and 65 years of age and there is no difference between 
mutated genes or gender (Vasen et al., 2001b). 
Watson et al. (2008), found that the risk of developing urinary tract cancers was 8%, which is highest 
among rarer cancer types in Lynch syndrome individuals. In their multicenter study, which includes 
over 6000 LS individuals from four different countries, the risk of having urinary tract cancer was 
higher (1.6-fold) among males than females. Among MSH2 carriers,  the  risk  was  7  times  higher  
compared to MLH1 mutation carriers. The highest risk of developing urinary tract cancer was between 
the ages of 50 and 70 (Watson et al., 2008).
The next most commonly observed “rarer” cancer in the study by Watson et al. (2008) was ovarian 
cancer  and  the  life-time  risk  of  having  it  was  nearly  7%  in  female.  In  Finland,  the  risk  was  
approximately 12% (Aarnio et al., 1999). Like urinary tract cancers also MSH2 mutation carriers were 
at a (2-times) higher risk of developing ovarian cancer than MLH1 mutation carriers. The highest 
ovarian cancer incidence was between ages 40 and 55 (Vasen et al., 2001b).
Brain tumors are also linked to LS with 1.6 standardized incidence ratios, but the significance of this 
finding is questionable.  Hematological cancers, larynx and lung cancers do not appear more 
frequently among LS individuals than non-mutation carriers (Watson and Lynch 1993).  
5.1.2 Endometrial cancer and Lynch syndrome 
Endometrial cancer (EC) is the most common gynecologic cancer in the Western world (Jemal et al., 
2008). Endometrial cancer can be divided in to two groups: type I and type II. Around 80 % of all 
cases are type I, in other words endometrioid endometrial cancer (Clement and Young 2002). Type I 
is less aggressive and it has a more favorable 5 year survival outcome (85 %) in all of its stages than 
type II (Jemal et al., 2008). Type I tumors commonly develop via precancerous lesions, which usually 
are a consequence of the unopposed estrogen effect for a long period of time. EC tumor type I 
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carcinomas might be described as estrogen dependent. Precursor lesions consist of different stages of 
hyperplasia and they can be divided into simple or complex based on architectural complexity and 
cytological atypia (Kurman and McConnel 2010). In fact, cytological atypia is regarded as the most 
critical morphological parameter predicting the progression of endometrial hyperplasia towards EC as 
suggested by a landmark study in the middle of 1980´s (Kurman et al., 1985).
Type II  ECs (10 % of  all  ECs)  consist  of  serous endometrium carcinomas and these tumors can be 
classified as high grade tumors. These tumors have a high risk of metastasizing and recurrence, and 
they are not estrogen dependent. There are no hyperplasias to precede type II EC, but endometrial 
atrophy is frequently present before the diagnosis of serouse EC (Amant et al., 2005).  
Women with Lynch syndrome have 32-60% risk of developing EC, which is higher than the risk of 
CRC in females (Aarnio et al., 1999). MSH6 mutation carriers have the highest risk of developing EC 
(Wijnen et al., 1999) compared to MSH2 and MLH1 mutation carriers (Vasen et al., 2001b).  
Therefore, Lynch syndrome women would benefit from a surveillance method to detect precancerous 
lesions before developing EC. In Finland, surveillance is recommended for women with Lynch 
syndrome after 30 to 35 years by the means of intrauterine sampling or ultrasound detection 
biannually or at three year intervals (Renkonen-Sinisalo et al., 2007). Surveillance is important, 
because the average age at onset of EC is approximately 46 years in LS women (Schmeler et al.,
2006; Renkonen-Sinisalo et al., 2007; Nieminen et al., 2009). Only MSH6 mutation carriers make an 
exception to this  rule,  since their  average age at  onset  in  EC is  over  50 years  (Hampel  et al., 2006; 
Wagner et al., 2001).   
A majority (80-85%) of the women with Lynch syndrome have endometrioid type I EC, usually these 
ECs can classified as Grade I or II, and Stage I (Broaddus et al., 2006). The rest (15-20%) of the EC 
tumors are type II, which means a worse prognosis than for type I tumors (Uharcek 2008; Silverberg 
and Ioffe 2003). Lynch syndrome women have a similar 5-year survival rate as women with sporadic 
EC (Boks et al., 2002). 
5.2 Familial colorectal cancer type X (FCCX) 
Familial  colorectal  cancer  type  X  (FCCX)  syndrome  resembles  Lynch  syndrome,  but  MMR  gene  
mutations are excluded. These patients, too, fulfill Amsterdam Criteria I (AC-I), or at least the revised 
Bethesda guidelines I-IV, see table 4. FCCX patients have an increased risk of colon cancer, but 
usually no other cancer, which is typical for Lynch syndrome. Their age at onset is around 60 years of 
age, which is older than for Lynch syndrome (Lindor et al., 2005).  
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Mueller-Koch et al. (2005) studied HNPCC-like families, none of which showed MMR gene 
mutations (were mutation negative). They observed that the localization of CRC differs significantly 
from LS. CRC in the mutation negative group occurs more frequently in the sigmoid colon and 
rectum, whereas in LS CRCs occur all over the colon. A big difference was also seen in the number of 
adenomas as in the mutation negative group 28% had adenomas and in the LS group only 14% had 
adenomas. It seems that the FCCX related colorectal cancer develops via the chromosomal instability 
(CIN) pathway (Mueller-Koch et al., 2005).
Lindor et al. (2005) hypothesized that cancers occur in FCCX patients only by chance. They also 
hypothesized that these families share the same environmental circumstances or a common genetic 
factor, which is behind this syndrome. Our studies indicate that there is indeed a genetic factor behind 
at least some of FCCX families (Nieminen et al., 2011).  
Linkage and other studies have been conducted to discover predisposing genes behind familial 
colorectal cancers. Wiesner et al. (2003) studied 53 patients, with a criterion that at least two siblings 
were affected with CRC or colon adenoma by the age of 65 or younger. The whole genome scan 
pointed out linkage to chromosome 9q22.2-31.2 with a p-value of 0.00045, which was associated with 
the risk of CRC or colonic adenomas by age ≤ 65. No mutated gene was found (Wiesner et al., 2003). 
Increased colon neoplasia in Ashkenazi-Jewish kindreds was linked to chromosome 15q13-14. The 
phenotype varies from serrated adenomas to colon cancer (Jaeger et al., 2003). Neklason et al. (2008) 
studied affected sibling pairs for colorectal cancer or high grade colon dysplasia. They investigated 
151 DNA samples from 70 families with a genome wide screen, using deCODE 1100 short tandem 
repeat markers. By nonparametric linkage analysis, three genome areas with a lod score of 2 or more 
were observed, suggesting that possible novel colon cancer susceptible gene/s resides on 7q31 
(Neklason et al., 2008). 
6. Tumorigenic pathways relevant for colorectal and other cancers 
There are several pathways that contribute to tumorigenesis. A common characteristic for all of these 
pathways is that they are usually very complicated, and act through the activation or inhibition of 
multiple genes. These pathways or signaling networks function to maintain the well-being of cells, but 
when disrupted chaos may follow (Vogelstein et al., 2000). 
The best-characterized pathways include the p53 and pRB1 signaling pathways. Also RAS, PTEN,
PI3K/AKT, and Hedgehog pathways play important roles in tumorigenesis. Some pathways relevant 
for colorectal cancers as well as various cancers common in Lynch syndrome are described below. 
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6.1 P53 pathway 
Cancer cells can acquire resistance to apoptosis by different strategies. The most commonly known 
loss of a proapoptotic regulator is a mutation in the p53 tumor suppressor gene. This mutation leads to 
the inactivation of the p53 protein, which is seen in more than 50% of human cancers. Inactivation of 
the p53 protein results in the loss of a key component of the DNA damage sensor, which negatively 
affects the function of the apoptotic effectors (Harris et al., 1996).  The primary function of p53 is to 
control cell death and also cell life through numerous signals from other genes. A mutation in p53 
itself or its connector genes can have a severe consequence, such as cancer (Vogelstein et al., 2000). 
There  are  at  least  three  types  of  mechanisms  that  can  activate  the  p53  pathway.  Ionizing  radiation  
causes DNA damage, which activates p53 pathway through protein kinases ATM and Chk2 
(activation is dependent on these kinases). ATM and Chk2 are responsible for adding phosphate 
groups to the other proteins. A double-strand break (which is one type of DNA damage) stimulates 
ATM, which in turn stimulates Chk2 (Vogelstein et al., 2000). Abnormal growth signals e.g. from the 
expression of Myc and Ras oncogenes triggers the second p53 pathway type. P14ARF protein is in turn 
responsible for the activation of the second p53 pathway (Sherr and Weber 2000). Protein-kinase 
inhibitors, ultraviolet light or chemotherapeutic drugs are responsible for the activation of the third 
p53 pathway. This pathway is not dependent on p14ARF, Chk2, or ATM (ataxia telangiectasia mutated) 
genes, instead it may be dependent on ATR (ataxia telangiectasia related) gene and casein kinase II 
kinases (Meek 1999).  
The activated p53 pathway works in a very complicated manner. For activation it needs DNA 
damage, ultraviolet light, or expression of oncogenes, which in turn stimulate enzymes that alter p53 
and MDM2 (p53 negative regulator). These alterations increase p53 levels. The expression of several 
target genes increases, when p53 binds to their regulatory regions. These genes usually inhibit 
tumorigenesis. MDM2 and p53 connect to each other by a negative feedback loop, which prevents the 
p53 pathway (Vogelstein et al., 2000).  
6.2 RAS pathway 
RAS  family  proteins  can  be  divided  into  two  parts:  RAS  and  RHO  family  members.  RHO  family  
proteins regulate the actin cytoskeleton, whereas RAS family proteins normally regulate cell growth 
through binding to GTP proteins. RAS family members KRAS, HRAS, and NRAS are widely 
mutated in malignant human tumors leading to activation (Lowy and Willumsen 1993).  KRAS is 
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expressed in almost all cells (Johnson et al., 1997).  Approximately 20 % of human cancers have 
mutations in RAS family genes, 85 % of these activating point mutations occur in KRAS, 15% in 
NRAS, and less than 1 % in HRAS. Allmost all point mutations in KRAS are in codons 12, 13, or 61 
(Bos 1989). 
When RAS is in its active state, it binds to GTP and it will interact with many protein families leading 
to their activation. RAS activates the RAF cascade, which leads to ERK activation through mitogen-
activated protein (MAP) kinase signaling. This leads to the activation of several other genes, which 
promote  transcription  and  cell  cycle  progression.  RAS  family  members  can  also  activate  the  PI3K  
cascade, which can activate AKT, PDK1, or RAC-GEFs cascades. AKT activation leads to the 
inhibition of BAD, Forkhead, or GSK3 cascades. PDK1 activation leads to activation of p70S6K or 
PKC cascades, and RAC-GEFs affects RAC activation. All of these changes affect cell survival, 
transcription, cytoskeletal signaling, or translation. RAS family members can also activate RALGDS 
signaling, which activates PLD or RAL cascade or inhibits Forkhead signaling. These alterations 
affect transcription, vesicle transport, or cell-cycle progression. Finally, mutated RAS family 
members  can  activate  PLCε signaling,  which  activates  PKC  or  Ca2+, and these activations affect 
calcium signaling (Downward 2003).
6.3 Wnt signaling cascade 
The primary function of Wnt genes is to encode secreted proteins. In many adult tissues, dynamically 
stable self-renewal and embryogenesis are controlled by Wnt signaling. Somatic and germline 
mutations in Wnt components cause cancer (mainly in the intestine, but in some other tissues as well) 
and multiple inherited diseases, respectively (Clevers 2006). Wnt signaling can be divided into 
canonical and non-canonical signaling cascades. Canonical signaling controls cell fate assessment and 
non-canonical signaling controls tissue polarity and cell migration (Katoh and Katoh 2007).   
When the Frizzled/LRP-5/6 (Fz/LRP-5/6) coreceptor complex binds to the cognate ligands, it 
activates canonical Wnt signaling. Fz interacts with the cytoplasmic protein Dsh, which acts upstream 
of GSK-3 and β-catenin. LRP-5/6 cytoplasmic tail connects to Axin (Davidson et al., 2005; Zeng et
al., 2005) through GSK3 and caseine kinase I-γ (CK1γ). GSK3 and CK1γ are the most important key 
players in canonical signaling initiation. Axin and Dsh connect to their membrane receptors, which 
mediate activation through DIX domains (Clevers 2006). A cytoplasmic protein, β-catenin, is the key 
player in canonical Wnt signaling. The stability of destruction complex regulates β-catenins and 
Axins, which are tumor suppressors, and act as a scaffold for the destruction complex. Axin interacts 
with other components – APC, β-catenin, and kinase family members CK1α,-ε,-δ, and the other 
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kinase family members GSK3α and GSK3β (Price 2006). GSK3α and GSK3β phosphorylate β-
catenin when the receptor complex of Wnt is not connected.  β-TrCP (F box/WD repeat protein) then 
recognized the phosphorylated  β-catenin, which is targeted and destructed by proteasomes (Aberle et 
al., 1997). This prevents transcription of the target genes of β-catenin. When Axin is  attached  to  
phosphorylated LRP by GSK3β and CK1γ, β-catenin is stabilized and it can travel to the nucleus 
where  it  releases  Groucho  from  Tcf/Lef  and  the  activation  of  the  target  genes  is  initiated  (Clevers  
2006), (Fig. 4). The target genes of β-catenin are DKK1, MYC, CCND1, and FGF20 among others 
(Katoh and Katoh, 2007).   
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6.4 Transforming growth factor-β signaling cascade 
The tumor growth factor-β signaling (TGF-β) cascade primarily aims at regulating cell differentiation, 
adhesion, and proliferation. It also regulates inflammation, haematopoiesis, skeletal development, and 
wound repair. Disruption of this signaling pathway leads severe consequences, e.g. cancer as well 
(Waite and Eng 2003).  
Bone  morphogenic  proteins  (BMPs),  activins,  and  TGF-β isoforms  are  all  members  of  the  TGF-β
family cytokines. Members of this family bind to the type II kinase receptors (serine/threonine), 
which then bind to type I receptors. Type II receptors phosphorylate type I receptors, which leads to 
activation of the receptors, and the SMAD protein mediates downstream signaling transduction. Three 
subtypes of SMADs exist: inhibitory SMADs, receptor-regulated SMADs, and common partner 
Figure 4. Canonical Wnt-signalling (Modified from Clevers 2006).  
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SMADs, iSMADs, R-SMADs, and Co-SMADs, respectively. Activin and TGF-β activation leads to 
R-SMADs-TGF-β activation,  whereas  R-SMADs  activation  is  a  result  of  BMP  receptor  activation.  
Receptor pathway activation leads to the phosphorylation of R-SMADs, which creates a complex with 
the SMAD4 Co-SMAD. After that, this complex migrates to the nucleus and indirectly or directly 
binds to DNA, by DNA binding proteins. Transcription of target genes is ready to begin (Waite and 
Eng 2003) (Fig. 5).   
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6.5 DNA mismatch repair cascade 
The mismatch repair (MMR) system is formed by a complex of many different genes that act 
together, (Fig. 6) (Jirichny and Nyström-Lahti 2000). Cell DNA is continuously threatened by 
external attacks from the environment as well as internal attacks by for example reactive oxygen 
species.  Damaged DNA has its own repair proteins for correction, which were firstly discovered in E. 
coli studies. Mut S, mutH, mutL, and mutU act in recognizing mispaired nucleotides, and give a signal 
to exonucleases and other repair proteins, and finally DNA polymerase corrects mispaired nucleotides 
(Service 1994; Fishel 1998).   
The incorrect pairing of the base G pairs with the base T by the erroneous action of a DNA 
polymerase leads to the formation of a sliding clamp, which surrounds the DNA. The single base 
Figure 5. Schematic overview of the TGF-β signalling pathway, (Modified from Waite and Eng 2003).
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mismatch is recognized by the MSH2-MSH6 (MutSα) complex. This complex departs from the 
mismatch  site,  and  the  MLH1-PMS2  (MutLα)  “matchmaker”  complex  binds  to  that  site.  This  
“matchmaker” complex travels along the new DNA chain untill it meets a DNA polymerase complex. 
DNA polymerase and proliferating cell nuclear antigen (PCNA) interact with the sliding clamp of the 
DNA MMR protein. The PCNA and DNA polymerase complex moves the daughter strand back to the 
mismatch site. Finally, the complex drops off from the DNA and resynthesis takes place, repairing the 
error. MSH2-MSH6 complexes can recognize both single pair mismatches and insertion deletion 
loops (IDLs). MSH2-MSH3 (MutSβ) complexes can recognize even larger insertion-deletion loops. 
MLH1 can also make connection with MLH3, PMS2, and PMS1 (which is not shown in the Figure 6) 
(Boland and Goel 2010). 
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Figure  6.  Diagram of  the  MMR pathway.  Base-base mispairs can be recognized by the MSH2-MSH6 
complex and “matchmaker” MLH1-PMS2 complex. DNA polymerase helps correct mispaired bases. 
When insertion loops are incorrectly incorporated into DNA, they are recognized by the MSH2-MSH3 
complex and corrected by the MLH1-MLH3 complex. The third form of mismatch is deletion loops, w 
hich can be recognized by e.g. the MSH2-MSH3 complex and corrected with help from MLH1-PMS2. 
(Modified from Jirichny and Nyström-Lahti, 2000). 
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AIMS OF THE STUDY 
I
To compare the molecular alterations in infrequently associated Lynch syndrome related tumors (such 
as uroepithelial, brain, and kidney carcinomas) to most frequently associated Lynch syndrome tumors 
(such as stomach, colon, and endometrial cancer). 
II 
To find out whether there are molecular changes associated with progression from normal 
endometrium to precancerous lesions to cancer by studying endometrial specimens from sporadic and 
Lynch syndrome cases. 
III
To find out whether there are differences in colorectal carcinogenesis according to ethnic origin, by 
studying sporadic colorectal cancer inEgypt and Finland and also FCCXs in Finland. 
IV
To find out predisposing genes for large colorectal cancer type X (FCCX) family by linkage analysis. 
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MATERIAL AND METHODS 
1. Patients and samples 
We have access to material on many Finnish LS families collected in the last 20 years. Today more 
than 200 Lynch syndrome families are known in Finland.  Most of the families fulfill Amsterdam 
criteria  I  (see  Table  4).  Many  of  the  individuals  from  these  LS  families  participate  in  clinical  
screening methods, such as annual or biannual colonoscopy screenings. Blood as well as tissue 
samples, which suit our studies well, can be taken during colonoscopy screening.    
Approximately 20 Lynch syndrome-like families exist in Finland, but their predisposing gene/genes 
are  unknown,  so  they  represent  FCCX.  Most  of  the  FCCX  families  fulfill  ACI  or  at  least  revised  
Bethesda I-IV guidelines, see tables 4 or 5.  
Additionally, we have acces to 69 unselected (sporadic) CRC samples from Egypt. Majority (65%) of 
the CRCs from the Egyptian series were diagnosed at less than 50 years of age.  The availability of 
clinical information from these patients was limited (e.g., information of family history was totally 
missing).  
Examined DNA samples were extracted from blood and formalin-fixed paraffin embedded blocks 
(FFPE) of tumor, precancerous lesions, and matching normal tissue whenever it was possible.  
Pathologists evaluated tumor and normal areas of the blocks and whenever it was possible, the areas 
were microdissected to get a good quality of sample.  
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Table 6. Number of the  samples that are included in studies I-IV
Tumor samples Lynch Sporadic FCCX Study
Colorectal cancer (CRC) from Finland 35  -  - I
 - 61 19 III
 -  - 18 IV
Gastric cancer 13 46  - I
Urological cancer 14  -  - I
Brain tumors 7  -  - I
Endometrial cancer (EC) 42  -  - I
14  -  - II
Complex atypical hyperplasia (CAH) 25 16  - II
Complex hyperplasia (CH) 10 14  - II
Simple hyperplasia (SH) 11 11  - II
Normal endometrium 50 21  - II
CRC from Egypt  - 69  - III
Methods that are used in corresponding study can be found from table 7. 
Table 7. Methods that are used in studies I-IV
Method Study I Study II Study III Study IV
Genetic linkage analysis *
MLPA *
Sequencing * *
SSCP *
LOH-analysis * *
SNuPE *
Conventional MSI analysis * * *
SP-PCR *
IHC * * * *
MS-MLPA * * *
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2. Genetic linkage analysis 
Genome wide linkage analysis was performed by using 384 microsatellite markers, with ABI3730xl 
DNA Analyzer. After microsatellite marker runs, assay success rates and sample success rates were 
calculated. The assay success rate tells how many microsatellite markers were succesful and sample 
success rates tells how many markers were succesfull per individual sample. All of the 384 markers 
were spread per 22 autosomal chromosomes and the X-chromosome. For example chromosome 
number 10 has 20 microsatellite markers, in 5-10 cM intervals.  
SW2 uses the Markow chain Monte Carlo (MCMC) algorithm, which is an estimate solution for the 
results. Even though these results are estimates, results were found to be in excellent agreement with 
the exact  results  when a comparison was made between the SW2 results  and from the program that  
gives exact results. Parametric linkage analysis gives the results for location scores (LOC-scores), 
which are comparable with multipoint LOD-scores. All the input-files were checked before analysis 
with Mega2 software package, which also construct the needed input-files. After Mega2 has accepted 
the entire file formats, SW2 can be launched. Once the run is complete the results are saved in the text 
file (Sobel and Lange 1996). 
3. Mutation analysis 
3.1 Multiplex ligation dependent probe amplification 
Multiplex ligation-dependent probe amplification (MLPA) (MRC Holland, Amsterdam, Netherlands) 
is a PCR-based method that can be used to detect large genomic rearrangements including deletions 
and amplifications (copy number variations CNVs).  It is possible to detect even 50 different 
sequences  of  genomic  DNA  simultaneously  by  MLPA.  We  used  the  SALSA  MLPA  P158  kit  for  
Juvenile polyposis syndrome (JPS) to detect deletions (or duplications) from BMPR1A gene of FCCX 
families’ index persons. This kit contains (among other) probes for all of the BMPR1A genes exons, 
except exon 7, due to the existence of a pseudo gene (www.mrc-holland.com). 
First DNA must be denaturated and the mixture of MLPA probes (two separate oligonucleotides) 
hybridized to the corresponding bases of the target sequence over overnight incubation. Both of the 
hybridized MLPA probes (near their targets) are ligated by the ligation reaction.  Ligated probes are 
amplified by PCR. The sums of the ligated probe products are equal of the count of the target 
sequences  in  the  sample.   Capillary  electrophoresis  is  used  for  separating  the  amplified  products  
(www.mrc-holland.com). 
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The probes of the P158-A1 JPS kit produce amplification products of 124-482 nt. It also contains 
control fragments, which detect successful of denaturation, X and Y chromosome control, and DNA 
quality. Normalization of the data is performed by dividing the particular peak area (exon of interest) 
of the sample by the total count of all peak areas. Further to obtain a dosage ratio (DR), the previous 
value was divided by the average peak value of the normal (healthy control).   
3.2 Sequencing 
When verification of an existing mutation is needed, the most sufficient method is direct sequencing 
of gene or area of interest. Primer design needs to be done for all of the exons of a particular gene, or 
exons which contain the mutation of interest.  First the gene of interest (or area of interest) was 
amplified by PCR and then, the products were run in a 2% agarose gel to see if PCR was succesful. 
After the gel run, the PCR products need to be purified by Exo-SAP-IT® PCRClean-up reagent.  
After Exo-SAP-IT® purification, the sequencing mix, forward and reverse primers, and purified PCR 
products  are  added to separate  tubes,  and the reactions run in the PCR machine.  After  the PCR run 
they are (“ready to run”) sequenced by the Applied Biosystems ABI 3730 automatic DNA sequencer.   
To confirm the germline mutations of LS patients, which were identified earlier from their families, 
exons from the MLH1, MSH2 and MSH6  genes were sequenced with the primers given by Chadwick 
et al. (2001). Naturally, only those samples were included in study I, which had a germline mutation 
in one of the MMR genes.  
From the positively linked area (10q23) few genes were sequenced to find out the predisposing gene/s 
in FCCX families. All the exons from the PTEN, MINPP1, and BMPR1A genes were sequenced from 
family 20, in study IV.  
3.3 Single-strand conformation polymorphism 
Single-strand conformation polymorphism (SSCP) is a method where the separation of two single-
stranded DNA fragments by electrophoresis in neutral polyacrylamide gel (PAGE) is possible. 
Nucleotide sequences in DNA can differ by only one position and SSCP can be used to detect those 
point mutations among other things. It has been used a lot previously, for example to search for 
genetic aberrations in human cancers. The discovery of genetic aberration by SSCP can be confirmed 
by direct sequencing (Orita et al., 1989).  
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Genomic DNA was used for SSCP analysis to detect alterations in the CNNB1 gene (exon 3) and the 
KRAS gene (exon 2), which were first amplified by PCR. PCR products were separated by PAGE in 1 
x MDE Gel solution (Cambrex Bio Science Rockland Inc., Rockland, ME). The gel was stained with 
silver nitrate to detect DNA. Observed conformational aberrations from the SSCP were sequenced to 
determine the exact location of the aberration in the nucleotide sequence. 
4. Loss of heterozygosity analysis
To examine a loss of heterozygosity in the APC gene, LOH analysis was performed by D5S1965 and 
D5S346 flanking microsatellite markers, in the MSH2 and MSH6 mutation carriers, in study I. We 
found a mutation in the BMPR1A gene  in  two  of  the  FCCX  families.  We  used  D10S1717 and 
D10S541 as  flanking  markers  to  see  if  LOH  was  detectable  in  several  adenomas  (and  few  CRCs)  
compared to normal tissue. We created intragenic LOH markers around mutated areas for both of the 
families. The LOH method is based on conventional PCR by flanking or intragenic markers where 
tumor DNA and a matching normal DNA sample are run at the same time. The areas of the normal 
and tumor alleles are visualized and they are compared to each other. Constitutional homozygotes are 
excluded  from this  analysis.  The  area  of  allele  1  from the  tumor  sample  (A1tumor)  is  divided  by  the  
area of allele 2 (A2tumor) and likewise, the area of allele 1 (A1normal) from the normal sample is divided 
by the area of allele 2 from the same sample (A2normal). Result from the tumor sample is divided by the 
result from the normal sample, as follows.  
LOH = 
Values of ≤ 0.6 or ≥ 1.67 in the LOH results were interpreted as a strict LOH. A strict LOH means 
that at least a 40 % decrease in another allele can be seen (Ollikainen et al., 2005). Values from 0.61-
0.75 and 1.33-1.66 are interpreted as a putative LOH (Cleton-Jansen et al., 2001). 
4.1 Fragment analysis 
Fragment  analysis  was  performed  after  MS-MLPA,  LOH,  Small  Pool  PCR,  or  conventional  PCR  
analysis among others. After getting PCR products from these above mentioned methods, we ran the 
products (except MS-MLPA) in the 2 % agarose gel to see if the method (and sample quality) was 
successful.  Based on the gel run, the products were diluted and pipetted into separate tubes or onto 
96-wells plates, which then were run by ABI 3730 XL. In this method, another primer (usually 
A1/A 2tumor 
A1/A2normal
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forward) has to be FAM stained to get a fluorescent PCR product, which then can be detected by the 
capillary electrophoresis sequencer. Fragments were analyzed by GeneMapper 4.0 software. 
4.2 Single nucleotide primer extension 
LOH can be detect also by single nucleotide primer extension (SNuPE). SNuPE is a method where the 
extension reaction is based on the incorporation of a single dideoxynucleotide (ddNTP), which yields 
the differential extension of the primers that are attached close to the polymorphic site. Genomic 
DNA  or  cDNA  fragments  (where  a  polymorphic  site  is  located)  are  amplified  by  PCR.  The  PCR  
products are used as templates for fluorescent labeled primer extension. Additionally, the extension 
reaction uses ddNTP and a combination of three dNTPs (Renkonen et al., 2005).  
LOH was determined from MLH1 gene polymorphism I219V (in exon 8 A/G). Primer extension 
continues until it reaches the I219V polymorphic position, where alleles have an A nucleotide, 
creating ddATP incorporation and chain termination. In the cases where the G allele is present in the 
MLH1 I219V site dGTP is incorporated causing strand elongation until the next A nucleotide 
(Renkonen et al., 2005). LOH was determined also by exploiting a coding polymorphism C/T to APC
gene nucleotide 1458 by SNuPE (Renkonen et al., 2005) in study I. The same values are used to 
determine the strict and putative LOH, which were used in the conventional LOH analysis, see page 
43.
5. Analysis of microsatellite instability 
5.1 Conventional MSI analysis 
Microsatellite instability analysis (MSI) is based on conventional PCR. Whenever possible we used 
the Bethesda panel markers i.e. the mononucleotide repeat markers BAT25 and BAT26 as well as the 
dinucleotide markers D2S123, D5S345, and D17S250 to detect MSI in tumor material (Boland et al., 
1998). When studying these repeats, matching with the normal counterpart is needed to compare the 
results of the tumor sample, especially when studying dinucleotide markers. After amplification, the 
PCR products were run in a 2 % acryl gel to detect the PCR products. The PCR products were run in 
an ABI capillary sequencer and after the fragment run; the results were analyzed with GeneMapper 
4.0 software. BAT25 produced 121 bp and BAT26 116 bp fragments. Categorization of the samples 
into microsatellite stable and –unstable was done according to different criteria depending on the total 
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number of markers used (e.g. the minimum requirement for MSI was two unstable markers when 
using the complete Bethesda panel and one unstable marker when using BAT25 and BAT26 only). 
5.2 Small Pool PCR 
DNA from the investigated tissue is diluted so that it represents only a single diploid genome of DNA, 
which is  used for  PCR.  PCR is  then divided in multiple  small  pools,  so that  it  is  probable to catch 
mutant fragments in one of these pools if the mutant fragment frequency is over 1% (Coolbaugh-
Murphy et al., 2004).   
The dinucleotide markers D5S346 and D2S123 (fluorescently labeled) were used (Boland et al., 
1998). In Small Pool PCR analysis, very heavily diluted (50pg) DNA samples were used. In study I, 
brain tumor DNA from one patient is divided into half of the 96-well plate and the other half consists 
of matching normal blood derived DNA. The plate also contains 16 negative controls (water) to see 
that no contaminations exist. Small Pool PCR was performed by using Expand High Fidelity Enzyme 
Reaction mix (Roche, Mannheim, Germany) in a 15 μl reaction volume and 62°C annealing 
temperature. Between zero to four alleles were amplified from each clone and those that diverged by 
more than 1 bp from the original allele size (specified by standard PCR) were interpreted as unstable. 
By dividing the number of unstable alleles with the total number of alleles (which is 39), the mutation 
existence was calculated, see the formula below. 
Mutation existence =
6. Protein expression analysis with immunohistochemical method 
Immunohistochemistry was used to confirm presence or absence of protein expression, by using 
different antibodies.  Table 8 shows information on the antibodies. Formalin-fixed paraffin-embedded 
blocks were cut with a microtome into 3.5-4 μm sections onto silanized glass slides.  Whenever it was 
possible primarily tumor and matching normal tissue from the same block were used. For staining, the 
DAKO EnVision+ system (Dako Cytomation) Peroxidase (DAB) according to manufacturer’s 
instruction was used. All of the antibodies were of mouse monoclonal origin. Antigen retrieval was 
done in a 1 mmol/L ethylenediamide tetraaceticacid (EDTA) buffer (pH 8.0) in a microwave oven for 
10 min.  If the β-catenin staining was nuclear more than 10% in tumors and not seen in matching 
Number of unstable alleles
Total number of alleles 
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normal tissue the expression was aberrant. More than 10 % of positive cells were used as a cut-off 
level in p53 protein stabilization (Gylling et al., 2007). When the expression was absent in tumors 
(negative) and the staining was positive (expression was present) in matching normal tissue the result 
was aberrant according to MMR proteins (MLH1, MSH2 and MSH6). 
Table 8. Information of the antibodies that were used in IHC.
Antibody Dilution Antigen retrieval  (10 min) Producer Clone
MLH1  1:70 EDTA (pH8.0)  1mM Pharmingen G168-15
MSH2  1:70 EDTA (pH8.0)  1mM Galbiochem FE-11
MSH6  1:70 EDTA (pH8.0)  1mM BD Transduction Laboratories 44
β-catenin  1:700 EDTA (pH8.0)  1mM BD Transduction Laboratories 14
P53  1:100 EDTA (pH8.0)  1mM DakoCytomation DO-7
7.  Methylation analysis 
7.1 Methylation specific multiplex ligation probe amplification 
The methylation specific multiplex ligation-dependent probe amplification method (MS-MLPA) is 
based on a modification of the traditional MLPA technique. The principle of this method is described 
in figure 7. In many tumors, tumor suppressor genes (TSG) are frequently silenced by methylation. 
SALSA (MRC-Holland) tumor suppressor kit ME001-C1 was used according to the manufacturers 
instructions (http://www.mrc-holland.com) to detect methylation in tumor (and matching normal) 
samples, in studies I-III. The kit contains 26 probes for 24 TSGs, such as the most common genes: 
RASSF1, APC, MLH1, CDH13, ESR1, PTEN, RARB, BRCA1, and BRCA2 (a complete list is available 
at www.mrc-holland.com). 
A target on the DNA contains the restriction site of the methylation-sensitive endonuclease HhaI.
DNA denatures and hybridizes with the probes, which are complimentary to their targets. After 
hybridization, the reaction is split into two tubes: one tube provides information on copy number 
changes and the other tube is incubated with the HhaI endonuclease and meanwhile the hybridized 
probes are ligated. Hybrids of probes and unmethylated DNA sample are digested by the HhaI
enzyme. Digested probes cannot be amplified during PCR and hence will not produce a signal during 
capillary electrophoresis. In contrast, if the DNA sample is methylated, the DNA-probe hybrids are 
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protected against HhaI digestion and the ligated probes will generate a peak.  After amplification and 
separation by capillary electroforesis results were analyzed with ABI Prism software GeneMapper 4.0 
(Applied Biosystems), see principle illustrated in figure 7. Normal DNA from a healthy invidual and 
tumor cell line DNA (RKO) were used as a controls for unmethylated and methylated samples, 
respectively (Joensuu et al., 2008). 
M
M
M
M
Methylated DNA target Unmethylated DNA target
1. DNA denaturization and hybridization with
complimentary probes
2. Ligation and digestion with
methylation sensitive enzyme (HhaI)
3. PCR amplification (with universal primers a and b) 
of probes, which are ligated and undigested
4. Fragment analysis by GeneMapper 4.0
a b
MS-MLPA results are calculated by comparing ligation fragments to undigested fragments. The 
reaction contains 15 additional control probes (without HhaI site)  which controls  the success of  the 
digestion. The digested peak area was divided by the undigested peak area and this sum was divided 
by the sum of the area of the control peaks, to determine methylation. As a cut-off value we set 0.15, 
Figure 7. Principle of the MS-MLPA (Modified from MRC-Holland, www.mrc-holland.com).
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which indicates  at  least  15% methylation of  DNA, in studies  I-II.  In study III,  the dosage ratio was 
reset at 0.25, which gave the best discrimination between normal and tumor samples.  
8. Statistical methods 
Differences between study and reference groups were calculated using Fisher´s exact test the t-test or 
the  χ2-test as a meaning to assess the statistical significance of the differences, p-value (p) 
(http://faculty.vassar.edu/lowry/VassarStats.html). Values less than 0.05 were considered as 
significant. All of these values were two-tailed. Statistical calculations of the genetic analysis from 
study IV are described more detailed in pages 39 and 56. 
RESULTS
  
1. Lynch syndrome tumor spectrum: Molecular data for rare Lynch syndrome tumors (I) 
We investigated molecular alterations in the bladder, ureter, kidney, brain, stomach, colon, and 
endometrial tumors from a well-characterized series of Lynch syndrome families, accurate numbers of 
the tumors can be found in table 6, page 37. The cohort (approximately 150 tumors in total) was based 
on a nation-wide registry and over 90 % of the families had MLH1 mutation. The MSH2 mutation 
occurred more frequently among bladder, ureter, and brain tumors than the MLH1 mutation. 
Conventional techniques, supplemented with the more sensitive small-pool PCR method, were 
applied to determine the MSI status by using the Bethesda panel marker set; BAT25, BAT26, D2S123,
D5S346, and D17S250. MSI in coding mononucleotide repeats was also analyzed, with previously 
published primers for the PTEN gene, exons 7 and 8 (Kuismanen et al., 2002), the ACVR2 gene, 
exons 3 and 10 (Deng et al., 2004), the TGFβ2 receptor gene, exon 3 and MRE11A, and intron 4 
(Gylling et al., 2007).
LOH at the APC region was analyzed by primer extension, which utilizes polymorphisms in APC
gene exon 11, as well as by standard fragment analysis using flanking microsatellite markers 
D5S1965 and D5S346. Exon 2 mutations from KRAS were screened by SSCP and direct sequencing. 
Digested peakarea
Undigested peakarea
Methylation  =
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Immunohistochemistry was used to analyze MMR protein and β-catenin expression. The methylation 
status of tumor suppressor gene promoters was determined by MS-MLPA.  
As a rule, LS tumors lacked the MMR protein corresponding to the germline mutation. This 
percentage was 100% for all tumors except brain tumros among which 75% showed decreased or lost 
MMR protein expression (Fig. 8). Although the tumors originated from verified LS individuals, the 
frequency of high-level MSI varies from high rate (100 – 96% for ureter, stomach, and colon), to 
intermediate (63 – 60% for endometrium and bladder) and low values (25 – 0% for kidney and brain), 
see figure 8.  By small-pool  PCR, MSI was detectable  also in those tumors that  were microsatellite-
stable by conventional techniques. 
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Active (nuclear) β-catenin was common in colon (74%) and endometrial tumors (53%), but rare or 
absent in the remaining tumors. Stabilization of p53 was frequent, from 33% to 60% and up to 75% in 
the kidney, ureter, and bladder tumors, compared to 20% or less in the remaining tumor types.  
Figure 9 shows the most methylated individual genes per different LS tumor type. In stomach tumors 
all nine individual genes (specified in Figure 9) were methylated and the highest >60%, >50% and 
>40% frequencies of methylation were seen for APC, CHFR and ESR1, respectively. In colon tumors 
the highest (>50%) methylation frequencies were among APC and ESR1, which were equally often 
methylated. Endometrial carcinomas showed very frequent methylation in RASSF1, whereas slightly 
Figure 8. MSI and MMR IHC results from different LS tumors. 
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less than half of the samples showed methylation in APC and CDH13 genes. Kidney tumors revealed 
equal rates of methylation (75%) for RASSF1 and CD44 genes. 
The only frequently (60%) methylated gene in ureter tumors was the RASSF1gene. In bladder cancers 
methylation was rare, whereas RASSF1, APC, CDH13, and GSTP1 all showed an equal rate (20%) of 
methylation. In brain tumors RASSF1 and GSTP1 showed methylation frequencies from over 40% to 
less than 60%, respectively, (Fig.  9). 
1.1 Summary of significant differences 
The ACVR2 tumor suppressor gene was significantly more often mutated in stomach and colorectal 
carcinomas than ureter carcinomas (32/33 vs. 1/5, p=0.00033). Active (nuclear) β-catenin was 
significantly (p=0.000066) more common in gastrointestinal (stomach and colorectal) carcinomas 
(61%) compared to total absence in urological carcinomas (0%). The difference in active (nuclear) β-
catenin expression was also significant (p=0.0016) between urological (0%) and endometrium (53%) 
carcinomas. APC LOH (strict or putative) was significantly more common in urological tumors (64%) 
compared to colorectal tumors (14%, p=0.016) or endometrial tumors (7%, p=0.0032).  KRAS exon 2 
mutation was seen in approximately one third of the colorectal tumors and none of the urological 
cancers (p=0.028). P53 stabilization occurred with similar rates among gastrointestinal cancers (15%) 
Figure 9. Methylation results of individual genes (only genes that were methylated in at least 30% in
any of the tumor categories are included in the comparison). The average number of methylated genes 
out of 24 is given in parentheses after each LS tumor type.  
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and brain tumors (17%), but was significantly more frequent (33-75%) in urinary tract tumors 
(kidney, ureter and bladder tumors p= 0.0047). 
Promoter methylation of tumor suppressor genes showed the highest average methylation frequencies 
in the colorectal (4.0) and stomach carcinomas (4.1) and the lowest in the urinary tract cancers (1.0-
2.3) and brain tumors (1.4). Differences   between the above mentioned values were; gastrointestinal 
(GI)-tumors vs. urinary tract (p=0.010) and GI vs. brain tumors (p=0.039). 
2. Molecular alterations in precancerous lesions: endometrial tumorigenesis in LS vs. sporadic 
cases (II) 
This so called Pipelle-study was based on LS females enrolled in clinical surveillance programs for 
endometrial cancer. Three subgroups were compared. The study group (I) consists of LS individuals 
(n=14 patients) who were (often several years later) diagnosed with endometrial cancer. The control 
group (II) consists of LS individuals (n=39 patients) who had not developed endometrial carcinoma in 
the follow-up, but had different types of hyperplasias. A third group (III) consists of females (n=62 
patients) who had no LS background and contributed normal and precancerous endometrial samples, 
(the numbers of the samples from LS and reference groups are indicated in Table 6).  
DC
BA
Figure 10. Hematoxylin-eosin stainings from the endometrium (A) SH, 
(B) CH, (C) CAH and (D) EC. Courtesy of Dr. Ralf Bützow. 
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All groups contained samples from normal endometrium, simple hyperplasia (SH), complex 
hyperplasia (CH), and complex atypical hyperplasia (CAH). EC samples originated only from group 
I. Characteristics of different histologies are shown in figure 10.  
We compared molecular data from the study groups (I and II) to the reference (sporadic) group III. 
MSI status was determinated by using mononucleotide repeat markers BAT25 and BAT26, and the 
dinucleotide marker D5S346.  MLH1, MSH2, and MSH6 antibodies were used to determine MMR 
protein expression. The MS-MLPA method was used to analyze promoter methylation statuses of 24 
different tumor suppressor genes.  
Majority (90%) of the LS women (groups I and II) had a MLH1 predisposing mutation, whereas 
MSH2 and MSH6 accounted for 6% and 4% respectively. A majority of the normal endometrium 
samples (93%) showed positive MMR protein expression, as expected for normal tissues. Among SH 
samples  (40%)  less  than  half,  CAH samples  a  majority  (92%)  and  CH samples  all  (100%)  showed  
decreased MMR protein expression corresponding to germline mutation (Fig. 11). All ECs (100%) 
showed decreased MMR protein expression corresponding to germline mutation.  
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Figure 11. MMR IHC results and MSI status in LS women. MSI status is shown separately by 
setting at least one unstable marker vs. at least two unstable markers as a requirement.  
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MSI  results  from  LS  patient  samples  showed  that  less  than  10  %  of  normal  endometrium  samples  
were unstable via one marker only. In SH samples less than 20 % of samples showed instability with 
one marker only. Slightly below 70% instability, via at least two markers, was seen in CH samples. 
Taken together (at least one and two unstable marker) 38 % instability was seen in CAH samples. In 
EC samples (from group I) MSI frequency was 64 %, (Fig. 11). 
Among LS women, the average number of methylated tumor suppressor genes out of 24 per sample 
was (in decreasing order) 3.1 in CH, 2.4 in CAH, 2.1 in EC, and 2.0 in SH. The lowest value of 1.1 
was seen in normal endometrium samples. Among the reference group, these values were 2.7 in 
CAHs, 2.4 in CHs, 0.6 in SHs, and 0.3 in normal endometrium samples, (see Figure 12). Results 
highlight a significant difference (p=0.0097) in methylation in normal endometrium from LS (1.1) 
compared to the reference series (0.3). The difference was also significant (p= 0.0016) in SH from LS 
(2.0) compared to the reference group (0.6). Interestingly no difference was seen in CHs compared to 
CAHs, (either between each other or in LS vs. reference group). When the same histologies from all 
the patient groups (I+II+III) were combined and a comparison was made between different histology 
categories, a significant difference was seen in normal endometrium (0.8) versus CH (2.7), 
p=<0.0001. A significant difference was seen also between normal endometrium (0.8) and CAH (2.5), 
p=<0.0001.
2.1 Methylation differences between individual genes in LS group 
There are differences in methylation frequencies among individual genes and between different types 
of histological lesions, and these were the most prominent for RASSF1, (Fig. 12). It showed 
significantly higher frequencies of methylation in CAHs (70%) compared to normal endometrium 
samples (12%) (p=0.006). When comparing CHs (100%) to normal samples (12%) in the LS series, 
the difference was also significant (p=0.006). The RASSF1 methylation difference was also significant 
between EC (45%) and normal samples (12%) p=0.04.   
Interestingly, all histological categories from LS individuals showed methylation in the CDH13 gene, 
and no significant differences are evident between the histological groups. We observed methylation 
in the CDH13 gene in normal endometrium in some of the LS individuals, over 10 years before EC 
occurrence. Among other genes with frequent methylation no significant methylation differences 
between histological categories were seen.  
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2.2 Comparison of promoter methylation differences between LS and reference group 
Frequencies of promoter methylation at selected loci in the sporadic reference group are given in 
figure 13, to enable comparison between the LS and reference series. In the reference series RASSF1,
CDH13, and GSTP1 showed significantly higher frequencies of methylation in complex hyperplasias 
compared to normal tissue or simple hyperplasia, (Fig. 13). When comparing methylation frequencies 
of individual genes between LS and reference groups some differences were seen e.g. for CDH13,
GSTP1, and RASSF1, mainly regarding normal tissue and SH, but not complex hyperplasias (Figs. 12 
and 13). In general, similarities were more striking than differences in the methylation patterns of LS 
vs. respective sporadic categories.  
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Figure 12. Methylation frequencies among endometrial tissues from LS mutation carriers i.e. groups I 
and II (only genes methylated in at least 30% of samples from at least one histological group are 
shown). The average number of methylated genes out of 24 is given in parenthesis after each 
histological type. 
Figure 13. Methylation frequencies among endometrial tissues from the reference series (group III). 
Only genes methylated in at least 30 % of samples from at least one histological group are shown. The 
average number of mehylated genes out of 24 is given in parenthesis after each histological type. 
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3. Molecular characterization of colorectal cancer from different ethnic origins (III)
Colon cancer cases from Egypt (n=69) were compared with a matching series of colorectal tumors 
from Finland (n=61) and FCCX (n=19) to evaluate if there are differences specific to the ethnic origin 
of the tumors. Almost half of the CRCs from Egypt were located in the rectum. In Finnish sporadic 
CRCs the main location seems to be the distal part of the colon (Laiho et al., 2003). The Egypt CRCs 
were also poorly differentiated or at the time of diagnosis they were at an advanced stage.  
We used the MS-MLPA method to study differently methylated tumor suppressor genes. All CRCs 
from Egypt and Finland were stained with the β-catenin antibody to evaluate the activation status of 
the Wnt-signalling pathway. To detect p53 stabilization, tumors were stained with the p53 antibody. 
All the Egyptian tumors were additionally stained with MLH1 and MSH2 antibodies to see if MMR 
was defective (this information was already available for Finnish CRCs). MSI analysis was performed 
using mainly mononucleotide repeat markers BAT25 and BAT26 from the Bethesda panel. MSI 
analysis divided the CRCs into MSS and MSI groups as appropriate.  
3.1 MSI and IHC results 
MSI frequency was very similar between Finnish (26%) and Egyptian (31%) sporadic CRC groups. 
All Finnish MSI CRCs had two unstable mononucleotide repeat markers, whereas Egyptian CRC 
tumors were designated as having MSI mainly by one mononucleotide repeat marker.  In the FCCX 
group  almost  all  CRCs  (95%)  were  MSS  and  MMR  proteins  (MLH1,  MSH2,  and  MSH6)  were  
expressed. In Egyptian CRCs, MLH1 was negative in 11% and MSH2 in 9% and cases with negative 
staining mainly represented those that also had MSI. Among Finnish CRCs, only MSI cases had been 
subjected to MMR protein staining, and 13/14 (93%) showed decreased or lost MLH1 expression (the 
basis of MSI remained unexplained in the remaining one case) (Joensuu et al., 2008) 
The p53 stabilization rate was similar among all of these groups, 63%, 51%, and 50% in Egypt, 
sporadic Finnish, and FCCX CRCs, respectively. β-catenin antibody staining showed remarkable 
differences between Egyptian and Finnish sporadic CRCs.  Approximately half of the Egyptian CRCs 
(59%) showed membranous β-catenin staining (suggesting non-active Wnt-signalling), leaving 41% 
of the Egyptian CRCs nuclear β-catenin compatible with active Wnt-signalling.  In Finnish sporadic 
CRCs, 78% showed nuclear expression and 22% membranous expression of β-catenin. Difference in 
β-catenin localization was highly significant (p=0.00006) between Egyptian and Finnish sporadic 
CRCs. 
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3.2 Methylation results 
When counting the average number of methylated tumor suppressor genes out of 24 per sample, there 
were no significant differences between Finnish (whether sporadic or familial) and Egyptian CRCs. 
However, when comparing the average methylation values between MSS CRC from Egypt (5.0) and 
sporadic MSS CRCs in Finns (2.0), the difference was highly significant (p=0.00002). For simplicity, 
MSS and MSI groups were put together in figure 14, which shows the individual genes that were 
frequently methylated in any of the three series. Among these genes, CDKN2B stands out. It was very 
often methylated in Egyptian CRC (more than 60%), and the difference was highly significant when 
compared with Finnish sporadic CRCs (less than 5 %) p=4.83E-10, or with FCCX (0%) p=4.83E-10.  
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DAPK1 was  highly  methylated  in  Egyptian  MSI  tumors  (50%)  compared  to  Finnish  sporadic  MSI  
(0%) (p=0.0038) (not shown in Figure 14). Finnish sporadic MSI CRCs showed frequent methylation 
of the MLH1 gene (63%), whereas among Egyptian MSI CRCs MLH1 was methylated in only 10 % 
(p=0.014; not shown in Fig. 14).  
All tumor categories showed similar methylation in ESR1, RARB, and APC genes. The FCCX group 
showed less frequent methylation in the CDH13 gene than in either sporadic group, and TIMP3 was 
unmethylated in FCCX, whereas both Finnish sporadic groups showed some methylation.  
Figure 14. Comparison of methylation frequencies in Egyptian and Finnish sporadic CRCs and 
FCCX. Only genes that were methylated in at least 30 % of tumors in any series are included. The 
average number of methylated genes out of 24 is shown in parentheses after each series. 
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A CIMP+ phenotype was considered to be present in tumor samples, when more than five tumor 
supressor genes were methylated out of 24, using MRC-Holland’s ME00-1C kit. It turned out that 
CIMP + phenotype was mainly seen in MSI cases from the Finnish sporadic series, whereas in Egypt 
CRCs CIMP + phenotype was associated equally often with MSI and MSS cases. 
4. Genome-wide linkage analysis to detect new predisposing genes in familial colorectal cancer 
(IV)
We  had  access  to  18  HNPCC  like  families  fulfilling  the  Amsterdam  Criteria  I  or  the  Bethesda  
guidelines B1, B4, or B5 (Table 9), and with MMR gene defects excluded. Clinically, these families 
resemble LS families, with the occurrence of CRC, extracolonial cancers, and many precancerous 
adenomas or polyps as well. The average age at CRC onset varies between 36 to 71.8 years (Table 9). 
One large FCCX family (family 20) was chosen for genome-wide linkage analysis to identify new 
predisposing genes.    
Table 9. Clinical characteristics of FCCX families
No. of affected individuals with
Family ID Colorectal cancer
Extracolonic
cancer only
Adenoma(s)
only
Criteria
fulfilled
Average age
at colorectal cancer 
diagnosis (yr)
F5 6 2 4 AI 36
F20 5 3 14 AI 61
F31 3 0 0 AI 45.6
F32 1 4 1 B5 59
F33 2 3 1 AI 36.5
F34 3 2 1 B1, B5 47.5
F42 3 1 1 AI 66
F45 2 0 1 B1, B4, B5 46
F47 3 6 1 B5 67
F49 3 4 0 B1, B4, B5 57
F56 11 12 3 AI 52.3
F68 4 3 0 AI 53.5
F74 4 6 2 AI 59
F75 5 0 1 B5 71.8
F79 2 3 0 B5 58.5
F80 4 8 0 AI 58.5
F84 6 6 6 AI 47.5
F86 4 5 3 AI 59.5
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For linkage analysis, 384 microsatellite markers spaced 10 cM apart were analyzed. Results were 
calculated using SimWalk 2 (SW2) statistical genetics computer software program. SW2 is a program 
that works in UNIX environment and it is possible to have 5 different linkage analyses: non-
parametric linkage (NPL), haplotype, identity by descent (IBD), mistyping evaluation of pedigree, 
and parametric linkage analyses.  
The following parameters were chosen for parametric linkage analysis: autosomal mode of 
inheritance, gene frequency 0.001, and phenocopy frequency 0.06. Additionally liability classes were 
set as follows. If the person was ≤ 30 years at diagnosis, penetrance for heterozygotes was 0.15 and 
liability class was 1. Liability class 2 was given when age of diagnosis was 31-45, and in this case 
penetrance for heterozygotes was 0.40. For liability class 3, the age of diagnosis was 46-60 and 
penetrance for heterozygotes 0.60. For liability class 4, the age of diagnosis was ≥ 61 and penetrance 
for heterozygotes 0.80. All of these parameters were needed for input files for SW2 and calculation of 
the results. 
Based  on  results  from SW2 linkage  analysis,  a  number  of  areas  with  tentative  linkage  (with  LOC-
scores of 1.2-1.6) were identified. Even though LOC-scores of 3.0 or higher are taken as definitive 
evidence of linkage, we decided to consider lower values, based on simulation results (where the 
highest value was 2.5). Simulation was performed before actual linkage analysis to determine the 
likely information content of the family. 
Family 20 revealed linkage to chromosome 10q23, and the area was narrowed down by additional 
microsatellite markers, see figure 15. Microsatellite markers that were used for fine mapping were 
from centromere (top) to telomere (bottom): D10S537, D10S607, D10S219, D10S1686, D10S1717,
D10S541, and D10S185, see figure 15. We investigated the linked area gene by gene to choose the 
best candidate genes to be screened for mutation by sequencing. Based on haplotype analysis, the 
linked area spanned from D10S537 to the end of the marker D10S541. As described below, 
BMPR1A, which is located between D10S1717 and D10S541, turned out to be the predisposing gene 
in this family.  
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Individual V:2 from the pedigree was partly recombinant (Fig. 15). Individuals IV:1 and IV:2 were 
totally recombinant and they turned out to be mutation negative, just like individual V:2. Individual 
III:4 linkage failed in the linkage analysis due to low quality DNA, but we got the result from 
sequencing and the individual was a mutation carrier. This pedigree is a good example of multiple 
carcinomas or adenomas, often with but sometimes also without mutation (IV:2, IV:1 and IV:9). It is 
questionable whether or not the adenomas would have been found without a colonoscopy surveillance 
program.  
The mutation found in family 20 was a 3 bp deletion (AGA) in exon 3 of BMPR1A gene (Table 10). 
Family 68 also revealed a mutation in BMPR1A:  a 24 bp deletion affecting the boundary between 
intron 1 and exon 2 (Table 10). The latter mutation leads to the skipping of exon 2 and a frameshift. 
No other mutations were found, in BMPR1A by exon-specific sequencing and MLPA in the present 
Figure 15. Family 20 pedigree, haplotypes, BMPR1A mutation status (+/-).  The boxes and circles indicate men 
and women, respectively. The black arrow indicates index person, the black box indicates occurrence of CRC, 
and the grey box/circle indicates extracolonic cancer. The single diagonal indicates death and diagonal stripes 
indicate adenomas or hyperplastic/inflammatory polyps in colon or rectum. 
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series of 18 FCCX families. Polymorphisms and mutations found in BMPR1A via sequencing can be 
found in table 10. 
Table 10. Summary of mutations and polymorphisms found in FCCX families
Location of variant FCCX Healthy controls
Pathogenic mutations
c.264-266del  (family 20) Exon 3  1/36 (0.028) 0/78 (0.0)
c.68-10_68+14del (family 68) Intron 1 - exon 2  1/36 (0.028) NA
Polymorphisms and 
unclassified variantsa
c.4C>Ab Exon 1 18/36 (0.50) NA
c.68-55C>T Intron 1 19/36 (0.53) 36/78 (0.46)
c.1343-134_1343-135ins9 Intron 9 10/36 (0.28) 10/78 (0.13)
c.1343-11T>C Intron 9 18/36 (0.50) 32/78 (0.41)
a Allele frequencies in FCCX did not signif icantly dif fer from healthy controls.
b Published polymorphism rs11528010 (allele frequency of 0.50 given in SNP database at NCBI).
NA, not analyzed
Variant allele frequency
Primer pairs were designed for intragenic markers to detect LOH in colon carcinomas and polyps 
from the two BMPR1A mutation positive families. Additionally, D10S1717 and D10S541 were used 
as flanking markers (see Figure 15). Among adenomatous polyps, 4/14 (29%) showed wild type (wt) 
LOH at D10S1717, the intragenic marker showed equally often wt and mutant (m) LOH 3/14 (21%), 
and D10S541 revealed equal distribution of wt and m LOH, 1/7 (14%) in family 20. Among 
hyperplastic (and inflammatory) polyps, 1/1 (100%) showed wt LOH at D10S1717. None of the 
carcinomas (n=2) or non-carrier adenomas (n=3) showed LOH with any of these markers. In Family 
68, the single carcinoma we had showed wt LOH with intragenic marker. 
DISCUSSION AND CONCLUSIONS 
1. Developmental mechanisms in tumors arising in LS (I, II) 
We investigated approximately 164 different LS tumors (150 tumors from study I and 14 EC tumors 
from study II) and 46 endometrium hyperplasias from LS individuals (study II). From sporadic cases 
we investigated all together 62 normal endometrium and different hyperplasia samples (study II). The 
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rationale was that by studying precancerous lesions it might be possible to detect the initial stage that 
reveals molecular alterations. By comparing differencies and similiarities between different LS 
tumors it might be possible to detect distinct molecular markers associated with specific tumor types. 
1.1 MMR pathway 
Kidney tumors showed relatively infrequent MSI (20 %) and brain tumors did not show MSI at all by 
conventional methods. CRC, urothelial cancers, EC, endometrial hyperplasias (CH and CAH), and 
gastric cancers showed MSI in 38-100% of specimens. Even though brain tumor and kidney 
carcinoma patients in this study were verified MMR mutation carriers, they did not seem to follow a 
typical microsatellite instability route. The Bethesda panel markers are optimal for CRCs but their 
performance in other tumors is not known. By using some other markers MSI might appear in kidney 
and brain tumors. On the other hand, it may not be necessary for tumorigenesis to have MSI; perhaps 
LS brain and kidney cancers arise through the failure of additional functions of MMR proteins such as 
apoptosis signaling, (Jiricny 2006) or via CIN. 
1.2 Wnt and p53 pathways 
Based on the β-catenin results, significant fractions of colorectal and endometrial tumors seem to 
follow the Wnt-signalling pathway. Urinary tract tumors have frequent p53 stabilization, based on p53 
IHC results, suggesting that this very common pathway in cancer is at least in part responsible for 
urinary tract carcinogenesis. 
1.3 CIMP pathway 
Based on our observation of CDH13 methylation being present in normal endometrium several years 
before EC development, CDH13 may play a major role in early endometrial tumorigenesis, especially 
in the LS group. Methylation of the RASSF1 gene may be important for advanced malignant 
phenotype.  EC, kidney,  brain,  and ureter  tumors,  as  well  as  sporadic and LS CH and CAH showed 
high methylation levels in RASSF1 gene. In sporadic EC tumorigenesis in particular it seems that also 
GSTP1 inactivation by methylation contributes to the malignant phenotype.  
The RASSF1 gene belongs to RAS family member. Its inactivation via promoter methylation 
contributes very frequently to multiple cancers (Table 11). The function of the Ras association domain 
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family 1 isoform A, better known as the RASSF1A gene, is to regulate apoptic and cell cycle 
checkpoint pathways (Donninger et al., 2007). 
H  or  T  cadherin,  better  known  as  CDH13, belongs to cadherin family members. The function of
CDH13 is to regulate calcium dependent cell adhesion. It has a possible role in regulating signal 
transduction pathways (Doyle et al., 1998; Kinch et al., 1997; Philippova et al., 1998). Clearly, it 
plays an important role in tumorigenesis of multiple cancers by aberrant promoter methylation (Table 
11).
Literature information derived from sporadic tumors (Table 11) supports our findings of high 
methylation frequencies of RASSF1A and CDH13. In RASSF1A, methylation frequencies vary from 
30% in bladder cancer to 99% in prostate cancer. Our RASSF1A and CDH13 methylation frequencies 
derived from LS individuals (Fig.  9) are broadly similar to the frequencies in table 11. 
Table 11. RASSF1A  and CDH13  methylation frequencies in different sporadic tumors according to literature compared
LS tumors from study I (Modified from Donninger et al. 2007).
Tissue LS Sporadic Ref. LS Sporadic Ref.
Bladder 20 % 30-50% Marsit et al ., 2006 20 % 29 % Maruyama et al ., 2001
Breast NA 95 % Yeo et al.,  2005 NA 33 % Toyooka et al ., 2001
Cervical/endometrium 71 % 45 % Cohen et al ., 2003 55 % 44 % Joensuu et al ., 2008
Colon 27 % 52 % Oliveira et al ., 2005 33 % 65 % Xu  et al ., 2004
Gastric 23 % 44 % Oliveira et al ., 2005 40 % 35 % Hibi  et al ., 2004
Glioma 43 % 57 % Hesson et al ., 2004 0 % 24 % Piperi  et al ., 2010
Prostate NA 99 % Jeronimo et al ., 2004 NA 31 % Maruyama et al ., 2002
Renal 75 % 56-91% Yoon et al ., 2001; Dreijerink et al ., 2001 0 % 3 % Morris et al ., 2003
RASSF1A CDH13
2. Multistep tumorigenesis leading to endometrial carcinoma (II) 
Kurman et al. (1985), made a histological follow-up study of endometrial pre-cancerous lesions from 
sporadic patients. They followed 170 patients with endometrial hyperplasia; of those 93 represented 
simple hyperplasia, 29 complex hyperplasia and 48 atypical hyperplasia. They concluded that atypia 
was a discriminating factor, because only 1.6 % of hyperplasia patients without atypia progressed to 
EC, whereas among patients who had hyperplasia with atypia, 23% progressed to EC. Since then 
hyperplasia with atypia (no matter whether it is complex or simple) has been a keystone in 
endometrial histology in considering the likelihood of progression to malignancy. Contrary to the 
traditional view, our results suggest that complex hyperplasia without atypia is equally important as 
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complex hyperplasia with atypia as precursor lesion of malignancy. However, since the number of the 
samples was low, more similar studies are warranted for firm conclusions. 
A limited number of published reports exist that suggest that MMR defects might be detectable in LS 
individuals before symptomatic endometrial carcinoma (Berends et al., 2001). Our results suggest that 
MMR defects as well as aberrant tumor suppressor gene promoter methylation are detectable in a 
proportion of LS women long before endometrial cancer development. More investigations are 
warranted to detect accurately the time points at which critical molecular changes appear during 
endometrial tumorigenesis. 
3. Colorectal tumorigenesis in cancers from the Egypt vs. Finland (III) 
We investigated 130 sporadic CRCs all together, 69 of which were from Egypt   and 61 from Finland; 
additionally 18 FCCX CRCs from Finland were examined. Our aim was to identify differences and 
similarities in CRC tumorigenesis depending on Eastern vs. Western origin.   
A majority of the CRCs from Egypt arose in the rectum, whereas among Western sporadic tumors, the 
distal colon predominated (Laiho et al., 2003). FCCX tumor location resembled Western sporadic 
tumors, in our study (III and IV) the location in the distal colon or rectum was associated with 
approximately 70% of FCCX cases. In FCCX patients studied by Mueller-Koch et al. (2005), the 
location seems to be similar to ours. The reasons for the different tumor distributions are unknown. 
CDKN2B methylation was characteristic of Egyptian sporadic CRCs. This finding is supported by Xu 
et al. (2004), who found out by methylation specific PCR combined with sequencing studies, that the 
CDKN2B gene was methylated in 68% of sporadic CRCs from China. It is unknown why this gene is 
epigenetically silenced in especially Asian and Middle-Eastern populations, but different exposures to 
some environmental influences are a possibility. 
MSI frequencies and p53 stabilization rates were broadly similar between Egyptian and Finnish 
sporadic CRCs. Differences were also seen; the spectrum of methylated tumor suppressor genes was 
different between Egyptian and Finnish sporadic CRCs. Wnt signalling activation differs significantly 
between Egyptian and Finnish sporadic CRCs. CIMP+ phenotype is a feature of MSS CRCs in Egypt 
and sporadic MSI CRCs in Finland.    
Based on our results it seems that carcinogenesis from these two ethnic populations is different. 
Tumorigenesis behind Finnish sporadic MSI CRC occurs via MLH1 promoter methylation (top panel 
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in Fig. 16), Finnish MSS sporadic CRC follows the bottom route (Fig. 16), and Egyptian sporadic 
CRC follows the middle route (Fig. 16). 
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4. Genetic basis of FCCX (III, IV) 
We have attempted to explore the genetic background of FCCX through tumor investigations (studies 
III and IV) and by genetic linkage analysis (study IV). Study IV resulted in the identification of 
BMPR1A as one of the susceptibility gene for FCCX. BMPR1A has previously been connected to 
juvenile polyposis syndrome (JPS). Our results suggest that the FCCX syndrome is connected to a 
BMPR1A mutation as well. Mutations that we found in the two FCCX families were novel and 
affected the extracellular part of the BMPR1A protein. Since this mutation location is not unique to 
FCCX, it is unlikely to explain the different phenotype seen in FCCX, but it may have some role in 
the phenotypic differences. 
Figure 16. Differences in sporadic colorectal carcinogenesis depending on ethnic origin. In Western MSI 
CRC, CIMP phenotype and/or BRAF mutation can promote transition from normal cell to serrated adenoma, 
which is followed by MLH1 hypermethylation and MSI leading to CRC. APC hypermethylation or mutation 
participates in the formation of Western sporadic MSS CRC, which usually develops from tubular adenoma, 
followed by p53 mutation and/or chromosomal instability (CIN). In Egyptian sporadic CRC, normal cells 
undergo changes to villous adenoma through KRAS and/or APC mutation and hypermethylation, which leads 
to CIMP phenotype and cancer (Modified from Issa, 2008).  
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In JPS, before CRC occurrence, polyps tend to have rounded shape, with wide erosion in their 
surfaces and a notable increase of stromal compartment. Additionally, JPS polyps have reactive and 
inflammatory alterations in epithelium and dilated and distorted glands (Jass et al., 1988). 
Approximately 20% of JPS is caused by a mutation in the BMPR1A gene (Howe et al., 2004). In our 
study (IV) all the adenomas were verified by a pathologist who is specialized in GI diseases. FCCX 
differs  from  JPS  many  ways.  In  FCCX  families  no  JPS-like  polyps  were  seen  and  no  significant  
polyposis was seen. The maximum was four polyps in one individual in one colonoscopy screening 
visit. In family 20, a high number of adenomas (14) were seen, in part reflecting the large pedigree 
size and the willingness to participate in colonoscopy screening among at-risk individuals (Table 9). 
Our finding can be considered a landmark observation considering other FCCX patients globally: now 
it is important to investigate, whether these patients have BMPR1A mutations  as  well.  If  BMPR1A
mutations are found, it will be interesting to see if they occur with the same frequency and affect the 
same parts of BMPR1A as in Finns. Our finding also raises the question whether there are mutations 
in other genes of the BMP-signaling pathway or in related pathways.  Our observation also suggests 
that other phenotypes can be caused by germline mutations in the same single gene.  
Even though one predisposing gene for FCCX was found in this investigation, the existence of 
additional susceptibility genes is likely. Mueller-Koch et al. (2005) suggested that FCCX occurs via 
the  CIN  tumorigenesis  pathway.  This  pathway  resembles  a  Western  sporadic  MSS  CRC  pathway  
(Fig. 16).  
5. Remarks about the methods used 
We used MSI and IHC analysis to stratify CRCs into specific subgroups and to divide HNPCC into 
LS and FCCX. Our findings confirm earlier observations that MSI and IHC analysis combined with 
AC I and II and the Revised Bethesda Guidelines are well suited for the discrimination of LS cancer 
from sporadic cancer or non-LS familial cancer. If MSI is present and one or several MMR proteins 
absent,  there  is  a  very  high  possibility  that  patient  belongs  to  LS  (which  needs  to  be  confirmed  by  
sequencing).  
We chose the MS-MLPA method to study methylation mainly because it suits for FFPE DNA 
samples very well, it is easy to use, and the method is not very time consuming. We have tested in our 
previous studies that bisulfite sequencing of different cell lines and MS-MLPA results were 
concordant (Joensuu et al., 2008). This conclusion is supported by Leong et al. (2011), in the 
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investigation of rectal cancer, where they concluded that results were concordant between bisulfite 
pyrosequencing and MS-MLPA. 
We chose linkage analysis with “old fashioned” microsatellite markers instead of SNP arrays, to 
search for predisposing genes in FCCX. A main reason was that several DNA samples were of FFPE 
origin. FFPE DNA is usually fragmented, and not of high molecular weight, the amount is limited, 
and the overall quality of the DNA is not very good. SNP-arrays need good-quality DNA. Secondly, 
the data analysis is not very time consuming in traditional linkage analysis by microsatellite markers.  
FUTURE PROSPECTS 
It is not properly understood why CRC and endometrial cancer are the most frequent cancers in LS. 
Studies into dietary or other environmental aspects might turn informative since such factors might 
shape the tumor spectrum. For example, Park et al. (1999) conducted a study where comparison was 
made  between  South  Korean  and  Dutch  LS  cancer  spectrum.  In  South  Korea,  gastric  cancer  and  
pancreatic cancer was more common and endometrial cancer was less common than in Dutch LS 
families.  The results suggest that those cancers that are common in the sporadic context are also 
involved in LS.  
CRC and endometrial cancer are not the only component tumors in LS, and it would be very 
interesting to know what other cancers belong to it too. For example, breast cancer is very frequent 
globally and its relationship to LS is unknown. Westenend et al. (2005) reported a case study, where a 
49-year old woman from a LS family was diagnosed with breast cancer. They concluded that the 
MSH2 mutation that was present in the patient was important for the breast cancer appereance, based 
on LOH, MSI and IHC results.  Müller et al. (2002) investigated 27 women who had synchronous or 
metachronous breast and colorectal cancer. CRCs of these women were MSI-H in 18.5 % of cases, 
whereas matched breast tumors were all MSS. Additionally, three women from LS families were 
diagnosed for breast cancer only, and all of them were MSS and IHC showed no alterations in protein 
expression.  Müller et al. (2002) concluded that breast cancer is not part of LS tumor spectrum, but 
more likely sporadic.  
We investigated EC precancerous lesions from LS individuals and found out that there may be 
molecular alterations several years before EC occurrence, even in normal tissue. This finding needs 
confirmation and additional research. Similar studies could be conducted on adenomas, precancerous 
lesions of CRC, and even normal colon tissue to see if molecular changes precede CRC development 
by several years.   
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All ECs of the present investigation originated from LS individuals.  Regarding the methylation 
results obtained in study II it would be very interesting to investigate sporadic endometrial cancers as 
well to see if the methylation trends are similar to those of LS-EC. 
Ethnic variation is involved (at least) in sporadic CRC formation when it comes to clinical and 
molecular differences. What are the factors behind these differences? As far as CRC is concerned, an 
environmental or dietary factor is possible and even likely. Are analogous ethnic differences seen in 
other cancers as well? More studies are warranted to confirm our results from the Asian or Middle 
Eastern sporadic CRC carcinogenesis. Especially it would be interesting to know why CDKN2B is 
such a frequent target in Egyptian CRCs. 
Considering FCCX syndrome, it would be fascinating to find out if there are other mutated genes as 
well. Based on, for example, differences in age at onset of CRC between FCCX families, there may 
be plenty of different predisposing genes. A good example is LS, where the average age at onset 
varies according to the MMR gene in question (lower in MLH1 and MSH2 compared to MSH6
mutation carriers). Approaches similar to those we applied combined with new technologies (such as 
next generation sequencing) can be used to identify the responsible genes in the remaining FCCX 
families. 
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